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This study aims to determine the prevalence and types of quinolone resistance and 
carbapenemases genes among different isolates from patients admitted to the University 
Hospital of Leipzig over a period of ten months. 
During the period from January 2011 through October 2011, a total of 50 carbapenemases 
isolates were recovered from patients of the University Hospital of Leipzig/ Germany. The 
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KPC, IMP, VIM, OXA-48, NDM-1, and aac-6-Ib genes as well as qnrA, qnrB, and qnrS 
genes were detected by multiplex PCR, respectively. 
Results showed that KPC gene was detected in 82% of the isolates. The qnrA, qnrS, IMP, 
NDM-1, and OXA-48 genes were not detected in any of the isolates while qnrB and VIM 
genes were found in 2%. On the other hand, aac-6-Ib gene was the most prevalent gene 
among the study isolates and composed a percentage of 96%. 
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Abstract 
Beta lactam resistance producing isolates of Enterobacteriacea and non-Enterobacteriacea 
have emerged since more than seventy years ago (Abraham and Chain, 1940). They are 
known to cause both community and hospital-acquired infections. Resistance against 
carbapenem is primarily mediated by the production of enzymes that destroy the beta lactam 
antimicrobials, which are produced by these isolates involving the expression of serine and 
metalobetalactamase genes KPC, IMP, VIM, NDM-1 and OXA-48. Quinolone resistance is 
predominanty mediated by mutations in the qnrA, qnrB, qnrS, and aac-6-Ib genes. 
Carbapenemase-producing organisms especially Klebsiella pneumoniae carbapenemases 
(KPCs) emerged as important pathogens especially among critically ill patients causing 
significant morbidity and mortality. This study aims to determine the prevalence and types of 
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quinolone resistance and carbapenemases genes among different isolates from patients 
admitted to the University Hospital of Leipzig over a period of ten months. 
During the period from January 2011 through October 2011, a total of 50 carbapenemases 
isolates were recovered from patients of the University Hospital of Leipzig/ Germany. The 
isolates were identified by biochemical tests and their susceptibility to antimicrobials was 
determined by the microbroth dilution method according to ISO standard. The KPC, IMP, 
VIM, OXA-48, NDM-1, and aac-6-Ib genes as well as qnrA, qnrB, and qnrS genes were 
detected by multiplex PCR, respectively. 
Results showed that KPC gene was detected in 82% of the isolates while 8% were KPC 
negative. The qnrA, qnrS, IMP, NDM-1, and OXA-48 genes were not detected in any of the 
isolates while qnrB and VIM genes were found in 2%. On the other hand, aac-6-Ib gene was 
the most prevalent gene among the study isolates and composed a percentage of 96%. Results 
also showed that KPC, and aac-6-Ib genes were detected in isolates collected from urine, 
blood, wounds, swabs, sputum, tracheal secretions, biopsies, and anal smears, while VIM 
gene was detected in one isolate collected from blood. The qnrB gene was found in one 
isolate collected from urine specimen. 
The wide spread of carbapenem and quinolone resistance-producing organisms is a critical 
problem that complicates the treatment of infections resulting from these organisms. 
Necessary measures must, therefore, be taken to limit their spread, which include appropriate 
antibiotic treatment, control of hospital infections, observe of personal hygiene, and the use of 
appropriate methods of sterilization and disinfection to prevent the dissemination of these 
organisms. 




1.1 Carbapenemases and Quinolone Resistance Determining Region 
mutations (QRDRm) 
1.1.1 Literature Review 
Resistance to β-lactam agents has been reported as early as 1940 (Abraham and Chain, 1940). 
Carbapenem resistance is of a special importance and produced by enzymes called 
carbapenemases (Queenan and Bush, 2007). The initial description of carbapenemase 
production was at the beginning of 1980s by a strain of Serratia marcescens in the United 
Kingdom and the United states (Yang et al., 1990, Naas T et al., 1994). 
These enzymes can hydrolyze penicillins, cephalosporins and carbapenems and are 
inhibited by clavulanic acid (Queenan and Bush, 2007). Infections caused by carbapenemases 
such as KPCs become established worldwide such as in United states, countries in South 
America, Europe, Israel, Germany and Greece (Paterson & Bonomo,2005, Vatopoulos, 2008, 
Kitche et al., 2009, Nordmann et al., 2009, Leavitt et al., 2010, Steinmann et al., 2011). In 
Asia, KPC was reported in China (Wei et al., 2007) Korea (Rhee et al., 2010) and Tiwan 
(Chung et al., 2011). Commonly, carbapenemase producing strains are also quinolone 
resistant (Yigit et. al., 2001, Bratu (C) et. al., 2005, Lomaestro et. al., 2006). Bacterial 
resistance should be a concern for physicians, it often results in treatment failure and leads to 
serious health problems (CDC, 2009, Borer et al., 2009, Daikos et al., 2009, Patel et al., 2008, 
Bratu (B)., 2005). 
The quinolone resistance was found to be related to mutations that lead to amino acid 
alterations in the quinolone-resistance determining regions (QRDRs) within the subunits 
which are involved in the DNA synthesis. These subunits inhibit the DNA gyrase; the 
topoisomerases II which is responsible for GyrA and GyrB genes, and topoisomerase IV 
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which is responsible for ParC and ParE genes that end with the survival of the bacteria 
(Hooper, 1999). 
The quinolone resistance genes (Qnrs) as QnrA, QnrB, and QnrS were also reported as 
inhibitor for the DNA gyrase and showed resistance to nalidixic acid (Martinez et. al., 2003). 
Furthermore, the presence of a novel gene, aac(6’)-Ib-cr encoding a fluoroquinolne-modifying 
enzyme (aminoglycoside acetyltransferase) have been detected as an important gene which 
plays a significant role in the mechanism of quinolone resistance (Machado et. al., 2006). 
The carbapenemases and QRDR genes are i.e found in K. pneumoniae; Escherichia 
coli (Carl et al., 2008), Pseudomonas aeruginosa (Villegas et.al., 2007), Shigella flexneri 
(Iyobe et al., 2000), Citrobacter spp (Chu et al., 2001), Klebsiella oxytoca (Kristóf et al., 
2010), Enterobacter cloacae (Lee et al., 2008), Serratia marcescens (Lambert et al., 1994), 
Salmonella enterica (Cheung et al., 2005), and most recently in an Acinetobacter baumannii 
strain (Robledo et.al., 2010). 
Resistance has a great potential for spreading among the organisms by extra 
chromosomal elements such as plasmids (Kang et al., 2005, Schwaber & Carmeli,2008, 
Queenan and Bush, 2007) as well as transposons, and the gene cassettes (Kang et al., 2005, 
Schwaber & Carmeli,2008). On the other hand, long-term care facilities and hospitalisation 
facilitate the spread of these organisms among people (Urban et al., 2008). Patients with 
unrecognized KPCs served as reservoirs for transmission during health care associated 
outbreaks (Samra et al., 2007). Early detection of carbapenemases and QRDR-producing 
organisms and introduction of strict infection control including hand hygiene and contact 
precautions can help control the spread of these organisms (Samra et al., 2007). 
1.2 Clinical Impact of Multiresistance  
Resistant may spread and pose broader infection-control problems in hospitals and 
community (Bruinsma et al., 2003). Increased mortality and morbidity rates have been 
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documented in multiple studies with different organisms in different specimen sites (Borer et 
al., 2009, Daikos et al., 2009, Patel et al., 2008, Bratu (B), 2005). Furthermore, children could 
be affected and the infections could be transmitted among the family members and among the 
students in schools (Garau et al., 1999). Finally, infections caused by carbapenemase 
producing organisms have been associated with increased treatment cost and hospital stay 
length (CDC, 2009). 
1.3 Mechanisms of Antibiotic Resistance 




Figure 1: Antibiotics; sites of action and Mechanisms of resistance. Modified with permission 
from the American Association for the Advancement of Science (Science1992;257:1064–
73).3 Image by: Lianne Friesen and Nicholas Woolridge 
 
1.3.1 Carbapenemases 
Beta lactams antibiotics consist of all antibiotic agents that contain a β-lactam nucleus in its 
molecular structure. This includes penicillins, cephalosporins, monobactams, and 
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carbapenems (Holten and Onusko, 2000). They work by inhibiting bacterial cell wall 
synthesis. Bacteria often develop resistance to β-lactam antibiotics by beta-lactamase 
enzymes synthesis (such as carbapenemases), enzymes that attack the β-lactam ring. They 
may be inhibited by β-lactamase inhibitors such as clavulanic acid (Fig: 2, 3, and 4) (Hawkey, 




Figure 2: Beta lactam ring destroyed by beta-lactamases enzymes 
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Figure 3: beta-lactamases enzymes coded for bla genes attacking beta-lactam antibiotics 
(David H., 2013). 
 
 
Figure 4: Clavulanic acid inhibiting beta-lactamases 
 
Beta-lactamase enzymes destroy the beta-lactam ring by two major mechanisms of action: 
1. In the most common mechanism, beta-lactamases have a serine based mechanism of 
action. They are devided into two major classes in carbapenemases (A and D) on the 
basis of amino acid sequence (class A: KPC, class D: OXA-48). They contain the 
active site consisting of a narrow longitudinal groove, with a cavity on its floor, which 
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is loosly constructed in order to have conformational flexibility in terms of substrate 
binding (Fig: 5) (Bisson et al., 2002). Close to this, lies the serine residue that 
irreversibly reacts with the carbonyl carbon of the beta-lactam ring resulting in an 
open ring (inactive beta-lactam) and regeneration of the beta-lactamase. (Fluit et al., 
2001; Page, 2002). 
 
 
Figure 5: The Molecular structure of serine based carbapenemases (Jawahar Swaminathan 
and MSD staff at the European Bioinformatics Institute).  
2. A less commonly group of beta-lactamases are the metallo beta-lactamases or class B 
beta-lactamases (Class B carbapenemases: IMP, VIM, and NDM-1). These use a 
divalent transition metal ion, most often zinc, linked to histidine or cysteine residue or 
both, to react with the carbonyl group of the amide bond of most penicillins, 
cephalosporins, but not monobactams (Fig: 6) (Fluit et al., 2001; Page, 2002) 
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Since the mid 1990s quinolone resistance started to increase in bacteria (Dalhoff, 1999). 
Fluoroquinolones are the only class of antimicrobial agents in clinical use that inhibit the 
bacterial DNA synthesis. They inhibit two bacterial enzymes: DNA gyrase and topoisomerase 
IV, which have essential roles in DNA replication (Higgins et al., 2003). The quinolones bind 
to the complex of each of these enzymes with DNA; the resulting topoisomerase-quinolone-
DNA ternary complex subsequently leads to a breaking DNA which ends with blocking the 
DNA replication enzyme complex. Ultimately, this action results in damage to bacterial DNA 
and bacterial cell death (Drlica et al., 2008; Drlica and Zhao et al., 1997, Hooper, 1999). 
The two main mechanisms of quinolone resistance are chromosomally encoded, being either 
modification of the quinolone targets with changes of DNA gyrase (gyrA) and/or 
topoisomerase IV (parC) genes that alter the conformation of target amino acid residues 
within the protein, or decreased intracellular concentration due to impermeability of the 
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membrane or overexpression of efflux pump systems (Oktem et al., 2008; Dalhoff, 2012; 
Allou et al., 2009; Poirel et al., 2006; Jacoby, 2005; Hernández et al. 2011). 
In addition to the chromosomal mutations in the QRDRs, plasmid-mediated quinolone 
resistance (PMQR) determinants may also reduce the levels of quinolone susceptibility 
(Martinez-Martinez et al. 1998, Robicsek et al. 2006, Hernández et al. 2011). 
The plasmid.mediated (transferable) fluoroquinolone resistance include several mechanisms: 
1. Qnr, 2. Aminoglycoside acetyl-transferase AAC(6´)-Ib-cr and other mechanisms (Tran and 
Jacoby, 2002; Poirel et al., 2008; . Robicsek et al., 2006; Strahilevitz et al., 2009; Poirel et al., 
2012; Rodr´ıguez-Mart´ınez et al., 2011). The Qnr proteins protect DNA from quinolone 
binding to gyrase and topoisomerase IV (Martinez-Martinez et al. 1998; Tran and Jacoby, 
2002; Nordmann and Poirel, 2005). The aac(6´)-Ib gene catalyzes acetylation of 
aminoglycosides while the aac(6´)-Ib-cr gene (a variant from aac(6´)-Ib gene) catalyzes 
acetylation of aminoglycosides and fluoroquinolone (Vetting et al., 2008). 
1.3.3 Mode of Carbapenemases and QRDR Genes Transfer (Plasmid and 
Chromosomal) 
The rapid spread and growing list of pathogens in which the resistant genes (such as KPC) 
have been isolated is probably due to its carriage mainly on plasmids (Jacoby and Bush, 2005; 
Nass et al., 2008; Medeiros,. 1997). Plasmids are the major vehicle for the spread of bacterial 
resistance, as they can be transferred between Gram negative bacteria by conjugation 
(Samaha-Kfoury and Araj, 2003) (Fig: 7). The transfer of resistance genes are not only 




Figure 7: The transfer of bacterial resistance between G -ve bacteria by conjugation 
1.3.4 Control the Spread of Beta Lactamases 
To minimize the spread of beta lactamases, Firstly, infection control practices efforts should 
be done by early identification of beta lactamases producing bacteria with in vitro testing 
(Todar, 2008, CDC, 2009), detecting colonization and preventing horizontal spread (Kochar 
et al., 2009). Secondly, standard precautions, especially hand hygiene and instruments 
sterilization should be observed (Todar, 2008). Furthermore, early detection of carriers; which 
include patients who were hospitalized and then transferred to another country, and the 
patients at risk such as patients who were in ICUs, patients who had transplantation 
operations, and immunocompromised patients (Miriagou et al., 2010, Nordmann et al., 2011). 
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1.3.5 Classification of Carbapenemases 
For β-lactamases two major classifications are being used: the Ambler molecular 
classification and the Bush-Jacoby functional classification (Ambler, 1980; Bush, 1988; Bush 
et al., 1995; Rasmussen and Bush, 1997). And two major molecular families: metallo-
carbapenemases and serine carbapenemases which are distinguished by hydrolytic mechanism 
at the active site (Bush et al., 1995). Metallo enzymes found to be inhibited by EDTA and 
contain at least one zinc atom at the active site that facilitates the hydrolysis of the beta-
lactam ring (Frere et al., 2005). Serine enzymes (contain serine at the active site) emerged in 
the mid to late 1980s and were found to be inhibited by clavulanic acid and tazobactam but 
not by EDTA (Medeiros and Hare, 1986; Yang et al., 1990, Rasmussen et al., 1996). 
1.3.5.1 The Ambler Molecular Classification 
The Ambler Molecular Classification (Fig: 8) is based on amino acid homology and not 
phenotypic characteristics and resulted in four known classes of beta lactamases (Huovinen et 
al., 1988; Jaurin and Grundstrom, 1981; Ambler, 1980). Carbapenemases are divided into 
three of four classifications which include classes A, B, and D. Classes A and D which 
include serine at their active site are considered as serine carbapenemases, where as class B 
contains metallo carbapenemases with zinc in its active site (Ambler, 1980, Paterson and 
Bonomo, 2005). Class B metallo carbapenemases have a wide spectrum activity against 
carbapenems, penicillins, and extended spectrum cephalosporins but not aztreonam (Queenan 
and Bush, 2007; Patel et al., 2009). These enzymes can be found in Gram negative bacteria 
such as Enterobacteriacea and others (Walsh et al. 2005). 
The major family of class A serine carbapenemases include KPC enzymes (Ambler et al., 
1991). To date, eight families of acquired metallo beta-lactamases, including IMPs, VIMs, 
SPM-1, GIM-1, AIM-1, SIM-1, NDM-1 and DIM-1, have been identified (Zhao and Hu, 
2010; Lee et al., 2005; Yong et al., 2009; Poirel et al., 2010). IMPs and VIMs, which belong 
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to the subclass B1, are the most frequent metallo beta-lactamases acquired by Gram-negative 
bacilli (Zhao and Hu, 2010; Walsh et al., 2005). In class B metallo carbapenemases the 
mainly three types refers to: IMP (imipenemase), VIM (Verona integron-encoded metallo-
beta-lactamase) and the recently reported NDM-1 (New Delhi metallo-beta-lactamase-1) 
(Ambler, 1980; Moellering, 2010). Class D include OXA type carbapenemase (oxacillin-
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Figure 8: The Ambler Molecular Classification for carbapenemases 
1.4 Carbapenemases Point Mutation Genes 
1.4.1.1 KPC-type Carbapenemase (Class A) 
The KPC-type carbapenemases refers to Klebsiella pneumoniae carbapenemases. They are the 
most commonly occurring molecular class A and functional group 2f. KPCs can hydrolyze 
multiple different antimicrobial agents such as fluoroquinolones, aminoglycosides, and β-
lactams including carbapenems, cephalosporins, penicillins, and aztreonam (Endimiani et al., 
 27 
2009; Castanheira et al., 2008) and are inhibited by clavulanic acid and tazobactam (Queenan 
and Bush, 2007). 
To date, ten KPC gene variants have been reported and classified from KPC-2 to KPC-1 
while KPC-1 was found to be identical to KPC-2 (Yigit et al. 2008). The KPC-2 to KPC-11 
genes are characterized by nonsynonymous single nucleotide substitutions within four codons 
(nucleotides: 147, 308, 716, and 814) (Wolter et al. 2009). 
Multiple studies reported KPC genes worldwide; KPC-2 (Nordmann et al., 2009), KPC-3 
(Nordmann et al., 2009), KPC-4 (Livermore et al. 2008; Palepou et al. 2005, Robledo et al. 
2007; Robledo et al. 2010), KPC-5 (45), KPC-6 (Aquino et al., 2008), KPC-7 (Perez et al. 
2010), KPC-8 (Gregory et al. 2010), and KPC-10 (Robledo et al. 2010) have been described 
in numerous countries, with KPC-2 and KPC-3 accounting for most epidemic outbreaks 
(Nordmann et al., 2009). 
The KPCs are predominantly found in K. pneumoniae; however, they have also been found in 
many other Enterobacteriaceae including Escherichia coli (Carl et al., 2008) Enterobacter 
species (Bratu (A) et al., 2005) Salmonella species (Miriagou (A) et al., 2003) Proteus 
mirabilis (Tibbetts et al., 2008) and Citrobacter freundii (Marı et al., 2010) as well as many 
other non Enterobacteriaceae including Pseudomonas aeruginosa (Villegas et.al., 2007) and 
most recently in an Acinetobacter baumannii strain (Robledo et.al., 2010). 
The first KPC isolates Klebsiella pneumoniae was found in the United States in North 
Carolina in 2001 and then spread in New York (Yigit et al., 2001; Patel et al, 2009; Kitchel et 
al., 2009). However, KPCs are now widely distributed worldwide and multiple studies 
reported the presence of KPC such as in Israel, China, Greece, South America, Germany and 
India (Queenan and Bush, 2007; Patel et al, 2009, Yigit et al., 2001, Arnold et al., 2011; 
Grundmann et al., 2010; Steinmann et al., 2011). 
In 2008, KPC-2 producing Klebsiella pneumoniae outbreak was reported in southern part of 
Germany (Wendt et al., 2010). In 2005, Naas and his colleagues reported the first case of 
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KPC-producing Klebsiella pneumoniae in France while the first outbreak of KPC-producing 
Klebsiella pneumoniae outside the United States was in Israel (Leavitt et al., 2007). 
Infections produced by KPCs are frequently identified among nosocomial pathogens and are 
associated with treatment failure and high mortality rates that reached at least 50% (Landman 
et al., 2007; Bratu (B) et al., 2005; Gasink et al., 2009). Combination therapy is recommended 
for the treatment of KPC infections (Lee and Burgess, 2012). The multiplex real-time PCR 
assay using molecular beacons was found to be robust, sensitive, and specific, allowing for 
high-throughput detection and classification of all KPC variants (Chen et al., 2011). 
1.4.1.2 IMP-type Carbapenemase (Class B) 
IMP-type beta lactamase refers to imipenemase, the Ambler Molecular class B (metallo 
carbapenemases) (Ambler, 1980), group 3 in the Bush-Jacoby Functional classifications 
(Bush et al., 1995). These enzymes hydrolyze carbapenems and extended-spectrum beta-
lactams (Livermore and Woodford, 2000) but are not inhibited by beta lactamase inhibitors 
such as as clavulanic acid, sulbactam, and tazobactam (Bush, 2001). 
The first identified acquired metallo beta-lactamases was IMP-1. It was detected in a clinical 
isolate of S. marcescens from Japan in 1994 (Osano et al., 1994; Ito et al., 1995). Untill the 
year of 2008, 24 variants of the IMP have been determined (Lahey Clinic, 2008). Recent 
investigations showed that the IMP family has at least 33 unique IMP variants 
(http://www.lahey.org/Studies), which may differ widely in regard to the primary sequence 
and biochemical activity. In August 2012, IMP-28 isolate was descovered in Klebsiella 
oxytoca in Madrid, Spain (Pérez-Llarena et al., 2012). Several IMP variants which are close to 
IMP-1 have been reported in the last few years; IMP-2 from an isolate of A. baumannii in 
Italy (Riccio et al., 2000), IMP-3 from Shigella flexneri in Japan (Iyobe et al., 2000), and 
IMP-4 from Acinetobacter and Citrobacter spp in China (Chu et al., 2001). 
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The IMP-7 shares 91% amino acid identity with IMP-1 (Gibb et al., 2002), while the IMP-10 
is a point mutation derivative of IMP-1 with a single base replacement leading to amino acid 
alteration (Iyobe et al., 2002). 
The blaIMP genes are usually horizontally transferred by integrons (Class one) carried by 
transferable large plasmids (Arakawa et al., 1995; Poirel et al., 2000, Shibata et al., 2003). 
IMP was found to be among Enterobacteriacea, Pseudomonas aeruginosa, Acinetobacter 
baumannii and other bacteria in Japan (predominantly IMP-1) as well as in Europe and the 
Far East (Hirakata et al., 1998; Ito et al., 1995; Senda (A) et al., 1996; Senda (B) et al., 1996; 
Riccio et al., 2000; Hawkey et al., 2001; Yano et al., 2001). 
1.4.1.3 VIM-type Carbapenemase (Class B) 
VIM-type beta lactamase refers to Verona Integron-encoded Metallo-β-lactamase. As IMP, it 
is in the Ambler Molecular class B (metallo carbapenemases) (Ambler, 1980), group 3 in the 
Bush-Jacoby Functional classifications (Bush et al., 1995). Until 2008, 22 VIM variants have 
been determined (Lahey Clinic, 2008). The name Verona Integron-encoded Metallo-β-
lactamase was given because the VIM was first isolated in Verona, Italy, in 1997 (Lauretti et 
al., 1999). 
These enzymes hydrolyze carbapenems and extended-spectrum beta-lactams (Livermore and 
Woodford, 2000) but are not inhibited by beta lactamase inhibitors such as as clavulanic acid, 
sulbactam, and tazobactam (Bush, 2001). 
VIM-2 is considered the most reported metallo beta-lactamase worldwide (Walsh et al., 
2005). 
Carbapenem resistance related VIM beta-lactamase production is considered a serious 
problem since they have high ability to spread (Richet et al., 2001). The VIM gene as IMP 
gene is horizontally transferable. 
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A total of 27 VIM family variants (VIM-1–27) have been assigned in the Lahey Clinic 
(www.lahey.org/Studies) and were found mainly in Pseudomonas aeruginosa (Castanheira et 
al., 2009; Siarkou et al., 2009; Schneider et al., 2008) and other pathogens such as 
Pseudomonas putida (Lombardi et al., 2002), Escherichia coli (Miriagou (B) et al., 2003), 
Klebsiella pneumoniae (Giakkoupi (A) et al., 2003), Klebsiella oxytoca (Kristóf et al., 2010), 
Enterobacter cloacae (Lee et al., 2008), Acinetobacter baumannii (Tsakris et al., 2006), 
Proteus mirabilis (Vourli et al., 2006), Citrobacter freundii (Yan et al., 2002) and Serratia 
marcescens (Lee et al., 2008). 
Treatment options of VIM-producing organisms are considered limited. Multiple studies 
showed that combination therapy increase the patient survival and is considered more 
effective against infections caused by P. aeruginosa (Chamot et al., 2003; Micek et al., 2005; 
Parkins et al., 2007). In a study carried out by Parkins and his colleagues in the period of 2002 
and 2004 suggested piperacillin–tazobactam as the backbone of most of the treatment 
regimens, but was still associated with frequent treatment failure. Furthermore, they 
commonly used aztreonam as a second beta lactam agent (Parkins et al., 2007), despite animal 
data showing questionable efficacy (Bellais et al., 2002). 
1.4.1.4 OXA-48-type Carbapenemase (Class D) 
OXA-48 refers to Oxacillinase beta lactamase, the Ambler Molecular Class D (Ambler, 
1980), and group 2d according to Bush-Jacoby Classification (Bush et al., 1995). OXA 
represented one of the most prevalent plasmid-encoded beta-lactamse families in the late 
1970s and early 1980s (Matthew, 1979; Medeiros, 1984; Simpson et al., 1980). 
They have been found mainly in Enterobacteriaceae and P. aeruginosa (Bush and Sykes, 
1987; Naas and Nordmann, 1999). OXA-48 was found in E. coli as well as in Enterobacter 
cloacae (Dimou et al., 2012) and others. The First OXA beta lactamase with carbapenemase 
activity was described by Paton et al. in 1993 in an Acinetobacter baumannii isolate, which is 
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found to be the most prevalent organism that carries the OXA carbapenemases (Afzal-Shah 
and Livermore, 1998). 
OXA-48 is plasmid encoded gene and have less than 50% amino acid identity to the other 
OXA members. It spread into multiple strains of several Enterobacteriaceae species by 
horizontal transfer (Dimou et al., 2012). It was discovered in a clinical K. pneumoniae isolate 
from Istanbul, Turkey (Poirel et al., 2004). OXA-48 has the ability to hydrolyze penicillins, 
imipenem, and expanded-spectrum cephalosporins (Poirel et al., 2004). 
In a study carried out by Mimoz and his colleagues, a lethal peritonitis model was induced in 
mice with a Klebsiella pneumoniae isolate producing the carbapenemase OXA-48. A single 
dose (up to 100 mg/kg) of the antibiotic piperacillin-tazobactam, imipenem-cilastatin, 
ertapenem, or cefotaxime has been injected. Ceftazidime had the highest efﬁcacy in vivo. 
Therefore, they recommended ceftazidime for the treatment of infections caused by OXA-48 
producers if they do not coproduce an extended-spectrum beta-lactamase or a plasmid-
mediated AmpC cephalosporinase (Mimoz et al., 2012). 
1.4.1.5 NDM-1-type Carbaenemase (Class B) 
NDM-1 type refers to New-Delhi Metallo beta-lactamase, the Ambler Molecular class B and 
group 3 according to Bush-Jacoby functional classification. It is a broad-spectrum β-
lactamase (carbapenemase) that is able to inactivate all β-lactams except aztreonam (Yong et 
al., 2009). The name New Delhi came from the Indian origin of the first reported case which 
was in 2009 in a Swedish patient who travelled to New Delhi and acquired a UTI caused by 
carbapenem resistant Klebsiella pneumoniae and E. coli strains. These strains showed multi 
resistance to all antimicrobial agents except colistin (Yong et al., 2009). Investigations for this 
patient indicated an NDM-1 positive E. coli.  
The NDM-1 gene can be easily transferred due to its location on plasmids which are easily 
transferable (Yong et al., 2009). These plasmids also carry a number of other genes which 
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convey resistance to all aminoglycosides, macrolides, and sulfamethoxazole. Consequently, 
making these isolates multidrug resistance and in some cases to all antibiotics including 
tigecycline and colistin (Kumarasamy et al., 2010). NDM-1 convey’s bacteria cause a wide 
range of infections, both in the community as well as in hospital settings (Kumarasamy et al., 
2010; Roy et al., 2011; Khan and Nordmann, 2012). 
NDM-1 was found to be among different Enterobacteriaceae spp including Klebsiella 
pneumonia, E. coli, E. cloacae (Sonnevend et al., 2013; Kumarasamy et al., 2010), Proteus 
spp (Kumarasamy et al., 2010), Citrobacter freundii (Poirel et al., 2011; Sonnevend et al., 
2013; Kumarasamy et al., 2010), K. oxytoca (Kumarasamy et al., 2010), Providencia spp 
(Kus et al., 2011), M. Morganii (Kus et al., 2011), Shigella boydii, and Vibrio cholerae 
(Walsh et al., 2011). 
Since the treatment options for infections caused by NDM-1 producing bacteria are very 
limited, the NDM-1 producing organisms are named the world’s newest “superbugs”. The 
term ‘‘superbugs’’ is a bacterium that carries resistance genes for many antibiotics (Salcido, 
2010). 
The best treatments for an infection caused by bacteria that produce NDM-1 are colistin and 
tigecycline (Stone et al., 2011). Colistin is infrequently used because of its toxicity, but it is 
often the only antibiotic to which NDM-1-producing bacteria are susceptible to (Falagas and 
Kasiakou, 2006). Few NDM-1-producing bacteria have shown sensitivity aztreonam (Liang et 
al., 2011). 
1.4.2 QRDR Point Mutation Genes 
1.4.2.1 QnrA-, QnrB-, and QnrS-types 
Resistance to quinolones is classically chromosomally mediated. However, a family of 
plasmid-encoded quinolone resistance genes (qnrA, qnrB, qnrC and qnrS) has recently been 
described (Robicsek (B) et al., 2006). The qnrA found to have at least 6 variants (qnrA1-
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qnrA6) as well as qnrB 6 variants (qnrB1-qnrB6) while qnrS 2 variants (qnrS1-qnrS2). The 
qnrB and qnrS share 41% and 60% amino acid identity with qnrA (Shin et al., 2009; 
Nordmann and Poirel, 2005). They act by protecting both DNA gyrase and topoisomerase IV 
from quinolone inhibition (Yamane et al., 2007). 
Qnr variants have been observed in clinical isolates, more frequently among strains producing 
plasmid-mediated, extended-spectrum β-lactamases (Robicsek (B) et al., 2006). 
Three major groups of Qnr determinants, qnrA, qnrB, and qnrS, have been identified in 
various enterobacterial species such as Klebsiella pneumoniae (Chen el al., 2006), Salmonella 
enterica (Cheung et al., 2005), Shigella flexneri (Hata et al., 2005), Escherichia coli 
(Mammeri et al., 2005), Enterobacter cloacae (Paauw et al., 2006), and many others. 
The first plasmid-mediated quinolone resistance Qnr (later termed qnrA) was from the United 
States and reported in 1998 for a Klebsiella pneumoniae isolate (Martínez- Martínez et al., 
1998). According to CLSI guidelines, Qnr provides resistance to nalidixic acid but only 
reduced susceptibility to fluoroquinolones. 
The treatment of quinolone resistant producing organism infections is considered limited. 
Ciprofloxacin, a member of the large and widely used fluoroquinolone group of antimicrobial 
drugs, is considered the empirical choice treatment of infections in adults (Jacoby et al. 2006). 
1.4.2.2 AAC-6-Ib-type 
AAC-6-Ib-type refers to a new variant of the common aminoglycoside acetyltransferase 
(Melano et al., 2003; Park et al., 2006). This gene harbours two base pair substitutions that are 
capable of acetylating some of the ﬂuoroquinolones such as ciprofloxacin and norfloxacin and 
aminoglycosides, thereby reducing their activities (Robicsek (C) et al., 2006). Previous 
studies have described several mechanisms for aminoglycoside resistance including the 
bacterial expression of drug-metabolizing enzymes, such as aminoglycoside N-6'-
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acetyltransferase-Ib (aac(6')-Ib) being the most common mechanism of resistance to 
aminoglycoside antibiotics, especially in Gram-negative clinical isolates (O'Neill, 2008). 
The aac(6')-I is calssified into at least six genes (aac(6')-Ia to aac(6')-If (Galimand et al., 
1993). The aac-6-Ib gene have been identified in various enterobacterial species such as 
Enterobacter spp. (Kim et al., 2009), Escherichia coli (Frasson et al., 2011; Kim et al., 2009; 
Park et al., 2006), Klebsiella pneumoniae (Kim et al., 2009), Pseudomonas aeruginosa 
(Galimand et al., 1993), Acinetobacter spp. (Miller et al., 1985; Teran et al., 1991), Serratia 
marcescens (Lambert et al., 1994), Enterobacter cloacae (Kim et al., 2010), and many others. 
The aac(6')-Ib gene is considered the most prevalent aminoglycoside modifying enzyme that 
confers resistance to tobramycin, kanamycin, and amikacin. It was first identified in 1986 in 
Klebsiella pneumoniae isolates (Tolmasky et al., 1986). 
Although the treatment options of aac(6')-Ib producing organisms infections are very limited, 
the EUCAST reported amikacin as intermediate for Enterobacteriaceae which are 
intermediate or resistant to tobramycin and susceptible to gentamicin and amikacin. 
1.5 Detection of Carbapenemases and QRDR Genes 
Detection of resistance genes is a crucial infection control issue because: 
1. They are often associated with extensive, sometimes total, antibiotic resistance 
2. Resistant organisms that have acquired a carbapenemase can be vectors responsible 
for carbapenemase transmission to other organisms (Thomson, 2010). 
Detection of carbapenemases is difficult. It can be detected by phenotypic as well as 
genotypic methods (Tenover, 2006).Carbapenemase producers are screened first by 
susceptibility testing The EUCAST recommended procedure to detect carbapenemases 
producing organisms involves an initial disk diffusion screening with disks containing 
imipenem, meropenem or ertapenem. Meropenem is considerd the best for sensitivity and 
specificity in terms of detecting carbapenemase-producers (Nordmann et al., 2012, Vading et 
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al., 2011). On the other hand, ertapenem has excellent sensitivity, but poor specificity 
(relative instability to ESBLs and AmpC β-lactamases in combination with porin loss) 
(Nordmann et al., 2012). Carbapenemase-producing Enterobacteriaceae often have MICs 
below the clinical carbapenem breakpoints (Nordmann et al., 2012; EUCAST, 2012; Tato et 
al., 2007). The MICs of carbapenemase-producing strains differ between strains, and some 
strains have MICs for carbapenems below the current clinical susceptibility breakpoints 
(Nordmann and Nass, 2009; Miriagou et al., 2010). 
Carbapenemases identification based on phenotype-techniques such as the modified Hodge 
test, are considered not highly sensitive and specific (Nordmann et al., 2012; Pasteran et al., 
2010). This is a phenotypic test which could be used to determine if reduced susceptibility to 
carbapenems is mediated by a carbapenemase (Anderson et al., 2007). On the other hand, 
Amjad A and his colleagues concluded that modified Hodge test is a simple test that can be 
performed in the routine laboratory (Amjad et al., 2011). The test showed 100% sensitivity 
and specificity for detection of KPCs according to Lee and his colleagues (Lee et al., 2001). 
In 2012, Nordmann and his colleagues developed the Carba NP test to rapidly identify 
carbapenemase producers in Enterobacteriaceae. The test based on in vitro hydrolysis of a 
carbapenem, imipenem (Fig: 9). Results showed that this test was 100% sensitive and specific 
compared with molecular-based techniques. Furthermore, it was found to be rapid (<2 hours), 
inexpensive technique that may be implemented in any laboratory (Nordmann (B) et al., 
2012). 
For the detection of fluoroquinolone resistance producing organisms, susceptibility testing 
with disks containing ciprofloxacin, norfloxacin, and nalidixic acid (which is a marker for 





Figure 9: Carba NP test for identification of carbapenemases in Enterobacteriaceae 
 
Multiple studies detected the resistance genes via multiplex PCR (Chmelnitsky et al., 2008; 
Moquet et al., 2011; Shibata et al., 2003). Molecular detection of carbapenemase genes is 
widely used but it is considered expensive, time consuming (at least 12–24 hours), and 
requires substantial expertise (Nordmann (B) et al., 2012). 
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2 Research Objectives: 
 
The general objectives of this research are: 
1. Genotype carbapenemases-producing organism isolates to determine the most 
common carbapenemases genes at the University Hospital of Leipzig. 
2. Determine genotypic-phenotypic relationships of these isolates. 
3. Determine the Quinolone Resistance Determining Region (QRDR) mutations. 
4. Determine alterations of resistance mechanisms over time in the KPC-positive 
organisms. 
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3 Materials and Methods 
3.1 Materials 
3.1.1 Bacteria 
4.1.1.1 Clinical Isolates 
A total of 50 clinical isolates of KPC-producing organisms were collected from hospitalized 
patients admitted to the University Hospital of Leipzig. Duplicate isolates were excluded, so 
that one isolate was collected for a patient, and those isolates were collected from a variety of 
clinical specimens including; Urine, blood, wounds, and others. 
4.1.1.2 Bacterial Strains 
Strains meeting the study criteria which previously confirmed as a KPC producing organism 
were stored at -70
◦
C. Consequently, all these strains were subcultured and used in the 
molecular identification process. 
4.1.1.3 KPC Genes Control Strains 
KPC 375/08 K. pneumonia strain was obtained from the University hospital of 
Leipzig/Institut of Microbiology and infection epidemiology and was used as a positive 
control strain for the KPC gene as well as K. pneumonia (Kpn1056) and E.coli (Eco3171) 
strains that were obtained from Freiburg University. Citrobacter freundii (Cit37, -38, -39, -43, 
and -44) and Enterobacter spp (Ent458) strains were obtained from Freiburg University and 
used as a positive control for qnrA, qnrB, and qnrS genes. P. aeroginosa VIM-2 strain was 
obtained from the University Hospital of Leipzig/Institut of Microbiology and infection 
epidemiology and used as a positive control strain for the VIM gene. Acinetobacter boumani 
IMP-1 strain was obtained from the University Hospital of Leipzig/Institut of Microbiology 
and infection epidemiology and used as a positive control for the IMP gene. E.coli (strain 
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396/11) was obtained from Robert Koch-Institut and used as a positive control for OXA-48 
gene. K.pneumoniae (strain 10-O 3/11) was obtained from Robert Koch Institut and used as a 
positive control for NDM-1 gene. K.pneumoniae (strain GNS-4240) was obtained from Ruhr 
University of Bochum and used as a positive control for aac-6'-Ib gene.  
3.1.2 Antimicrobial Susceptibility Testing and Culture Media 
Potential KPC-producing strains were previously confirmed at the Institute for Microbiology 
of the University Hospital of Leipzig by MIC values according to EUCAST guideline. 
MacConkey agar was used for the KPC-producing isolates subculture. 
3.1.3 Electrophoresis Chemicals 
Agarose, ethidium bromide, loading die, and PCR ladder (100bp) were prepared for running 
the study genes. 
3.1.4 PCR Primers and Chemicals 
All strains were examined for the presence of KPC, qnrA, qnrB, qnrS, aac(6`)-Ib, IMP, VIM, 
OXA-48, and NDM-1 genes using multiplex PCR. The primers, their sequences and amplicon 
size which were used in this study are shown in table 1. 
 




bla-KPC-F 5`-ATGTCACTGTATCGCCGTCT-3` 424bp (Pillai et al., 2009) 
bla-KPC_R 5`-TTTTCAGAGCCTTACTGCCC-3` 424bp (Pillai et al., 2009) 
qnr-A-F 5`-ATTTCTCACGCCAGGATTTG-3` 516bp (Robicsek (C) et al., 2006) 
qnr-A-R 5`-GATCGGCAAAGGTTAGGTCA-3` 516bp (Robicsek (C) et al., 2006) 
qnr-B-F 5`-GATCGTGAAAGCCAGAAAGG-3` 469bp (Robicsek (C) et al., 2006) 
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qnr-B-R 5`-ACGATGCCTGGTAGTTGTCC-3` 469bp (Robicsek (C) et al., 2006) 
qnr-S-F 5`-ACGACATTCGTCAACTGCAA-3` 417bp (Robicsek (C) et al., 2006) 
qnr-S-R 5`-TAAATTGGCACCCTGTAGGC-3` 417bp (Robicsek (C) et al., 2006) 
IMP-F 5`-GGAATAGAGTGGCTTAAYTC-3` 447bp * 
IMP-R 5`-TCGGTTTAAYAAAACAACCACC-3` 447bp * 
VIM-F 5`-GATGGTGTTTGGTCGCATA-3` 390bp * 
VIM-R 5`-CGAATGCGCAGCACCAG-3` 390bp * 
OXA-48-F 5`-GCGTGGTTAAGGATGAACAC-3` 438bp (Poirel (2) et al., 2011) 
OXA-48-R 5`-CATCAAGTTCAACCCAACCG-3` 438bp (Poirel (2) et al., 2011) 
NDM-1-F 5`-GGTTTGGCGATCTGGTTTTC-3` 621bp (Poirel (2) et al., 2011) 
NDM-1-R 5`-CGGAATGGCTCATCACGATC-3` 621bp (Poirel (2) et al., 2011) 
aac(6`)-Ib-F 5`-TTGCGATGCTCTTATGAGTGGCTA-3` 482bp (Chemelnitsky et al., 2009) 
aac(6`)-Ib-R 5`-CTCGAATGCCTGGCGTGTTT-3` 482bp (Chemelnitsky et al., 2009) 
Table 1: Nucleotide sequence, and size of the primers used for multiplex PCR 
* Leipzig University Hospital/Institut of Microbiology and infection epidemiology 
 
3.1.5 Pulsed Field Gel Electrophoresis (PFGE) 
All PCR products were examined using PFGE. The PFGE allows separating much larger 
pieces of DNA than conventional agarose gel electrophoresis (Achtman and Morelli, 2001). 
The performance of PFGE is similar to a standard gel electrophoresis except that instead of 
constantly running the voltage in one direction, the voltage in PFGE is periodically switched 
among three directions. In addition, this technique easily measures the genome size and 
characterizes various strains at the DNA level (Basim and Basim, 2001).  
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3.2 Methods 
3.2.1 Carbapenemases Clinical Isolates 
All clinical isolates which were collected from patients of the University Hospital of Leipzig 
as KPC producing organisms were stored at -70◦C. Isolates were subcultured by streaking on 
MacConkey agar and incubating them at 37◦C for 24 hours and their presumptive 
identification was made on the basis of growth characteristics and a set of biochemical tests.  
3.2.2 Disc Diffusion Method and MIC Values 
The procedure was carried out according to EUCAST guidelines. The antimicrobial disks 
which were used contain imipenem, ertapenem, tigecycline, and other antibiotics. Results 
were interpreted and recorded as resistance (R), Intermediate (I), or susceptible (S). The 
isolates antimicrobial susceptibility test and the MIC values results were taken from the 
Institute for Microbiology of the University Hospital of Leipzig. 
3.2.3 Pulsed Field Gel Electrophoresis 
All PCR products were examined using PFGE according to BIO-RAD CHEF genomic DNA 
plug Kit manual as described below. 
Bacterial culture was inoculated into 50 ml of LB Broth and then a final concentration of 
180µg/ml of chloramphenicol were added and incubated for 1 hour. A twenty-fold dilution of 
the bacterial suspension was made using 1 ml bacteria, 1 ml Gram Crystal Violet, and 18 ml 
saline. The 2% CleanCut agarose solution was melt using a microwave and the solution was 
equilibrated to 50◦C in a water bath. For a final concentration of 1% agarose, 0.5 ml of Cell 
Suspension Buffer was used per ml of agarose plugs. For each ml of agarose plugs, 5 x 10
8
 
cells were removed then centrifuged for 3 minutes in a microcentrifuge at 10000 rpm at 4◦C. 
The cells were resuspended in the cell suspension buffer and the cell suspension was 
equilibrated to 50◦C. The calculated volume of 2% CleanCut agarose was combined with the 
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cell suspension and they were mixed gently. The cell/agarose mixture was kept at 50◦C then 
the mixture was transferred to plug molds using sterile transfer pipettes and then the agarose 
was allowed to solidify. The solidified agarose plugs were pushed into a conical centrifuge 
tube containing lysozyme solution the plugs were incubated for 2 hours at 37◦C. The 
lysozyme solution was then removed and the plugs were rinsed with sterile water. Proteinase 
K was then added as a reaction buffer for each ml of agarose plugs and then the plugs were 
incubated overnight at 50◦C without agitation. The plugs were then washed four times in 1x 
Wash Buffer and were incubated for 1 hour at room temperature with gentle agitation. 
Finally, the plugs were stored at 4◦C in 1x Wash Buffer. 
3.2.4 Detection of the KPC Gene 
Multiplex PCR was utilized to detect the presence of KPC gene. The DNA extraction was 
performed as described below. 
3.2.4.1 DNA Extraction 
The extraction of the isolates DNA was made according to the manual of Qiagen. Few 
bacterial colonies were harvested in 1ml normal saline and mixed by vortexing until dissolved 
completely. The suspension was centrifuged for 5 minutes at 7500 round/m. The supernatant 
was removed and the pellet was then resuspended in 180µl of ALT buffer and then was mixed 
by vortexing until it is completely resuspended. A volume of 20µl of Proteniase was added to 
the solution and mixed using the vortex. The suspension was left in the shaker for 1 hour at 
56◦C. The solution was then mixed by the vortex for 15 seconds and centrifuged for 1 min at 
8000 round/min. The AL lyses buffer was added at a volume of 200µl and the tubes were 
mixed by vortex and centrifuged for 20 seconds at 8000 round/min. A volume of 200µl of 
Ethanol was added to the suspension as a neutralization solution then mixed by vortex and 
centrifuged for 1 min at 8000 round/min. The supernatant was removed and then placed in 
another eppendorf tube with a spin column, then centrifuged for 1 min at 8000 round/min. 
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The spin column was then transferred to a new eppendorf tube. The first washing solution 
(AW1) with a volume of 500µl was added and the suspension was then centrifuged for 1 min 
at 8000 round/min. The spin column was then transferred to a new eppendorf tube. A volume 
of 500µl of the second washing solution (AW2) was added and centrifuged for 3 min at 14000 
round/min. The spin column was transferred to a new eppendorf tube and centrifuged for 1 
min at 14000 round/min as an additional step to make sure that the washing solution is 
completely gone. The spin column was then placed in a new eppendorf tube and 130µl of AE 
buffer was added. The suspension was incubated for 1 min at room temperature and then 
centrifuged for 1 min at 8000 round/min. Finally, the spin column was removed and the 
suspension formed which contains the DNA was kept at -70◦C until used for all of the 
research genes. 
3.2.4.2 The Master Mix and the Working Solution 
The Master Mix reagents were used in concentrations which gave the best gene bands in the 
gel electrophoresis. The working solution of the PCR master mix was prepared by adding 
0.2µl of each primer (the forward and reverse primers), 5µl of 10Xbuffer, 4µl of 25mM 
MgCl2, 1,25µl dNTP`s 10mM, and 0.25µl of Taq polymerase and Finally 37.1µl of the free 
Dnase/Rnase water. Each PCR reaction was carried out using 2µl DNA and 48µl of the 
previously prepared Master Mix in a final volume of 50µl. 
 
3.2.4.3 The PCR Conditions 
The amplification conditions were used according to previously programmed PCR conditions 
made by the microbiology and infections epidemiology laboratory staff and  involved an 
initial denaturation step at 95◦C for 2 min, 30 cycle denaturation at 95◦C for 20 seconds, 
annealing at 55◦C for 30 seconds, extension at 72◦C for 40 seconds, followed by a final 
extension step at 72◦C for 3 min and then cooled at 4◦C for ∞. The PCR annealing 
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temperature was considered according to the following equation: 4 * (C+G) + 2* (A+T) - 
5◦C. 
The PCR products were detected in 1.5% agarose gel in the presence of DNA ladder and 
loading dye, then placed in the Ethedium Bromide for at least 30 minutes and then 
photographed. Precautions were taken to prevent the samples from being contaminated by 
each other or from the skin and to keep out of the toxicity of the Ethedium Bromide. These 
precautions included the use of prealiquoted PCR reagents, gloves, and disposable tips. The 
preparation of the amplification reaction mixtures and the analysis of the amplified products 
were performed in separate areas. 
3.2.5 Detection of qnrA, qnrB Genes 
Multiplex PCR was utilized to detect the presence of qnrA and qnrB genes separated. The 
DNA extraction was performed as described above. 
3.2.5.1 The Master Mix and the Working Solution 
The working solution of the PCR master mix was prepared by adding 2µl of each primer (the 
forward and reverse primers), 5µl of 10Xbuffer, 5µl of 25mM MgCl2, 2µl of 10mM dNTP`s, 
and 0.5µl of Taq polymerase and Finally 29.5µl of the free Dnase/Rnase water. Each PCR 
reaction was carried out using 4µl DNA and 46µl of the previously prepared Master Mix in a 
final volume of 50µl. This Master Mix was used at the same reagents concentrations for both 
qnrA and qnrB genes. 
3.2.5.2 The PCR Conditions 
The amplification conditions were the same in detection the qnrA and the qnrB genes and 
were used according to Robicsek (C) et al., 2006 with few modifications. They involved an 
initial denaturation step at 94◦C for 1 min, 32 cycle denaturation at 94◦C for 20 seconds, 
annealing at 53◦C for 30 seconds, extension at 72◦C for 40 seconds, that is followed by a final 
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extension step at 72◦C for 6 min and then cooled at 4◦C for ∞. The PCR annealing 
temperature was considered according to the following equation: 4 * (C+G) + 2* (A+T) - 
5◦C. 
The PCR products were detected in 1.5% agarose gel in the presence of DNA ladder and 
loading dye, then placed in the Ethedium Bromide for at least 30 minutes and then 
photographed. 
3.2.6 Detection of qnrS Gene 
Multiplex PCR was utilized to detect the presence of qnrS gene. The DNA extraction was 
performed as described above. 
3.2.6.1 The Master Mix and the Working Solution 
 
The working solution of the PCR master mix was prepared by adding 4µl of each primer (the 
forward and reverse primers), 5µl of 10Xbuffer, 5µl of 25mM MgCl2, 2µl of 10mM dNTP`s, 
and 0.5µl of Taq polymerase and Finally 25.5µl of the free Dnase/Rnase water. Each PCR 
reaction was carried out using 4µl DNA and 46µl of the previously prepared Master Mix in a 
final volume of 50µl. 
3.2.6.2 The PCR Conditions 
The amplification conditions were used according to Robicsek (C) et al., 2006 with few 
modifications and  involved an initial denaturation step at 94◦C for 1 min, 32 cycle 
denaturation at 94◦C for 20 seconds, annealing at 53◦C for 30 seconds, extension at 72◦C for 
40 seconds, that is followed by a final extension step at 72◦C for 6 min and then cooled at 4◦C 
for ∞. The PCR annealing temperature was considered according to the following equation: 4 
* (C+G) + 2* (A+T) - 5◦C. 
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The PCR products were detected in 1.5% agarose gel in the presence of DNA ladder and 
loading dye, then placed in the Ethedium Bromide for at least 30 minutes and then 
photographed. 
3.2.7 Detection of IMP Gene 
Multiplex PCR was utilized to detect the presence of IMP gene. The DNA extraction was 
performed as described above. 
3.2.7.1 The Master Mix and the Working Solution 
The working solution of the PCR master mix was prepared by adding 0.4µl of each primer 
(the forward and reverse primers), 5µl of 10Xbuffer, 4µl of 25mM MgCl2, 1.25µl of 10mM 
dNTP`s, and 0.25µl of Taq polymerase and Finally 34.7µl of the free Dnase/Rnase water. 
Each PCR reaction was carried out using 4µl DNA and 46µl of the previously prepared 
Master Mix in a final volume of 50µl. 
3.2.7.2 The PCR Conditions 
The amplification conditions were used according to previously programmed PCR conditions 
made by the microbiology and infections epidemiology laboratory staff and  involved an 
initial denaturation step at 95◦C for 2 min, 30 cycle denaturation at 95◦C for 1 min, annealing 
at 53◦C for 1 min, extension at 72◦C for 1 min, that is followed by a final extension step at 
72◦C for 3 min and then cooled at 4◦C for ∞. The PCR annealing temperature was considered 
according to the following equation: 4 * (C+G) + 2* (A+T) - 5◦C. 
The PCR products were detected in 1.5% agarose gel in the presence of DNA ladder and 
loading dye, then placed in the Ethedium Bromide for at least 30 minutes and then 
photographed. 
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3.2.8 Detection of VIM and OXA-48 Genes 
Multiplex PCR was utilized to detect the presence of VIM and OXA-48 genes separated. The 
DNA extraction was performed as described above. 
3.2.8.1 The Master Mix and the Working Solution 
The working solution of the PCR master mix was prepared by adding 0.3µl of each primer 
(the forward and reverse primers for VIM and OXA-48 genes), 5µl of 10Xbuffer, 4µl of 
25mM MgCl2, 1.25µl of 10mM dNTP`s, and 0.25µl of Taq polymerase and Finally 34.3µl of 
the free Dnase/Rnase water. Each PCR reaction was carried out using 4µl DNA and 46µl of 
the previously prepared Master Mix in a final volume of 50µl.  
3.2.8.2 The PCR Conditions 
The amplification conditions were used according to previously programmed PCR conditions 
made by the microbiology and infections epidemiology laboratory staff and  involved an 
initial denaturation step at 94◦C for 10 min, 36 cycle denaturation at 94◦C for 30 seconds, 
annealing at 52◦C for 40 seconds, extension at 72◦C for 50 seconds, that is followed by a final 
extension step at 72◦C for 5 min and then cooled at 4◦C for ∞. The PCR annealing 
temperature was considered according to the following equation: 4 * (C+G) + 2* (A+T) - 
5◦C. 
The PCR products were detected in 1.5% agarose gel in the presence of DNA ladder and 
loading dye, then placed in the Ethedium Bromide for at least 30 minutes and then 
photographed. 
3.2.9 Detection of NDM-1 Gene 
Multiplex PCR was utilized to detect the presence of NDM-1 gene. The DNA extraction was 
performed as described above. 
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3.2.9.1 The Master Mix and the Working Solution 
The working solution of the PCR master mix was prepared by adding 0.5µl of each primer 
(the forward and reverse primers), 5µl of 10Xbuffer, 3µl of 25mM MgCl2, 1.25µl of 10mM 
dNTP`s, and 0.25µl of Taq polymerase and Finally 34.5µl of the free Dnase/Rnase water. 
Each PCR reaction was carried out using 5µl DNA and 45µl of the previously prepared 
Master Mix in a final volume of 50µl. 
3.2.9.2 The PCR Conditions 
The amplification conditions involved an initial denaturation step at 94◦C for 10 min, 32 cycle 
denaturation at 94◦C for 30 seconds, annealing at 57◦C for 40 seconds, extension at 72◦C for 
50 seconds, that is followed by a final extension step at 72◦C for 5 min and then cooled at 4◦C 
for ∞. The PCR annealing temperature was considered according to the following equation: 4 
* (C+G) + 2* (A+T) - 5◦C. 
The PCR products were detected in 1.5% agarose gel in the presence of DNA ladder and 
loading dye, then placed in the Ethedium Bromide for at least 30 minutes and then 
photographed. 
3.2.10  Detection of aac-6-Ib Gene 
Multiplex PCR was utilized to detect the presence of aac-6-Ib gene. The DNA extraction was 
performed as described above. 
3.2.10.1 The Master Mix and the Working Solution 
The working solution of the PCR master mix was prepared by adding 0.3µl of each primer 
(the forward and reverse primers), 5µl of 10Xbuffer, 4µl of 25mM MgCl2, 1.25µl of 10mM 
dNTP`s, and 0.25µl of Taq polymerase and Finally 38.9µl of the free Dnase/Rnase water. 
Each PCR reaction was carried out using 5µl DNA and 45µl of the previously prepared 
Master Mix in a final volume of 50µl. 
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3.2.10.2 The PCR Conditions 
The amplification conditions involved an initial denaturation step at 94◦C for 10 min, 35 cycle 
denaturation at 94◦C for 1 min, annealing at 59◦C for 1 min, extension at 72◦C for 1 min, that 
is followed by a final extension step at 72◦C for 10 min and then cooled at 4◦C for ∞. The 
PCR annealing temperature was considered according to the following equation: 4 * (C+G) + 
2* (A+T) - 5◦C. 
The PCR products were detected in 2% agarose gel in the presence of DNA ladder and 
loading dye, then placed in the Ethedium Bromide for at least 30 minutes and then 
photographed. 
3.2.11 Agarose Gel Electrophoresis 
The agarose gel was prepared by suspending agarose at a concentration of 1.5% (w/v) in 150 
ml of 1X TAE buffer. The agarose was heated in the microwave for 3 min until completely 
dissolved, then was cooled for 10-15 min, and poured into the mini electrophoresis cell. After  
1 hour solidification of the gel, the comb and the gates were removed. A volume of 10µl of 
each DNA amplified product was mixed with 5µl of loading dye and applied to the gel. The 
PCR DNA ladder was also applied and the gel was run at 70 Volts for 1 hour, then placed in 
the Ethedium Bromide for at least 30 minutes and then photographed. 
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4 Statistical Analysis 
SPSS Software (version 16.0) was used for data analysis including pearson correlation 
analysis. Pearson Correlation was used to indicate how the values of KPC Positive and aac-6‘-
ib Positvie are related to each other in conjuction with an external factor (eg. Leipzig during 





Where r is Pearson correlation 
Y is KPC Positive or aac-6‘-ib Positvie  




5.1 Bacterial Isolates 
During the period from January 2011 to October 2011, a total of 50 isolates of 
carbapenemases were collected from the University Hospital of Leipzig by the Microbiology 
department (Duplicate isolates were excluded). 
5.2 Organisms Responsible for the Carbapenemase/ QRDR-enzymes 
Production 
Out of the 50 isolates that were found to be positive for carbapenemase and QRDR-producing 
organisms, 44 isolates were Klebsiella pneumoniae (88%), two E. coli (4%), two 
Enterobacter cloacae (4%), one Proteus mirabilis (2%), and one Acinetobacter baumanii 
(2%) (Fig: 10). The E. coli, Enterobacter cloacae, Proteus mirabilis and four of the Klebsiella 
pneumoniae isolates were KPC negative. The two aac-6´-Ib negative isolates were Klebsiella 
pneumonia. 
 
Figure 10: Carbapenemase/QRDR-producing organisms 
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5.3 The Source of the Clinical Isolates 
Fifty clinical isolates of carbapenemase-producing organisms were collected from five major 
sources; Urine (16), Blood (5), swabs (9), wound (7), and other sources (13) which include: 
sputum (3), tracheal secretions (5), anal smears (3), and biopsies (2) (Fig: 11 and 12). 
 
 
Figure 11: The source of the collected isolates 
 
Figure 12: Other sources for the collected isolates 
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The major source of the study collected clinical isolates was from urine followed by swabs 
and wounds. Blood specimens had the lowest percentage among the major collected 
specimens. 
Clinical isolates collected from other specimens; other than the major specimens (urine, 
swabs, and wound) were mainly collected from tracheal secretions followed by sputum and 
anal smears and finally biopsies. 
5.4 Pulsed Field Gel Electrophoresis 
All PCR products were examined using PFGE according to BIO-RAD CHEF genomic DNA 
plug Kit manual as described above. Results showed that 41 isolate showed the same patterns 
while 9 isolates showed different patterns (Fig: 13). After testing the presence of KPC gene 
by PCR test, the 9 isolates which showed different patterns were all KPC negative. 
 
 
Figure 13: Pulsed Field Gel Electrophoresis for some of the isolates 
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5.5 Detection of KPC Gene by PCR 
The KPC gene of 424 bp was amplified in all collected isolates by multiplex PCR as 
described above. Positive and negative controls were used. The band was detected for the 
gene and for the positive control while none in the negative PCR blank (Fig: 14). 
 
 
Figure 14: KPC (424 bp) gene electrophoresis. *(+): positive control, (-): negative control, L: 
Ladder 
 
The 50 isolates on gel electrophoresis were not all positive for KPC, although the MIC values 
and the antimicrobial test showed multiresistance KPC. Nine isolates showed no bands on the 
gel and the test was repeated two times to confirm that these isolates are KPC negative. These 
negative KPC isolates showed different patterns on PFGE than the KPC positive. As a result, 
the prevalence of the KPC gene was 82%.  
5.6 Detection of qnrA by PCR 
The qnrA gene of 516 bp was amplified in all collected isolates by multiplex PCR as 
described above. Positive and negative controls were used. The band was detected for the 




Figure 15: QnrA (516 bp) positive control 
 
 
Figure 16: QnrA (516 bp ) gene electrophoresis: *(+): positive control, (-): negative control, 
L: Ladder 
 
Results showed that all the 50 isolates were negative for qnrA gene; no bands appear in the 
gel except the positive control which was strongly positive. The prevalence of qnrA gene 
among the study isolates were 0%. 
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5.7 Detection of qnrB Gene by PCR 
The qnrB gene of 469 bp was amplified in all collected isolates by multiplex PCR as 
described above. Positive and negative controls were used. The band was detected for the 
gene and for the positive control while none in the negative PCR blank (Fig: 17). 
 
 
Figure 17: QnrB (467 bp) gene electrophoresis: *(+): positive control, (-): negative control, L: 
Ladder 
 
One of fifty isolate (isolate number 3) showed a band in the gel electrophoresis and was 
considered qnrB positive isolate. As a result, the prevalence of the qnrB gene was 2%. This 
isolate was collected from a urine sample and it was also a KPC positive isolate. Furthermore, 
this isolate also showed aac-6'-ib gene positive. So, isolate number 3 carried KPC, qnrB, and 
aac-6'-ib genes. 
5.8 Detection of qnrS Gene by PCR 
The qnrS gene of 417 bp was amplified in all collected isolates by multiplex PCR as 
described above. Positive and negative controls were used. The band was detected for the 




Figure 18: QnrS (417 bp) gene electrophoresis: *(+): positive control, (-): negative control, L: 
Ladder 
 
Results showed that all 50 study isolates were qnrS gene negative; no bands appeared in the 
gel electrophoresis. As a result, the prevalence of the qnrS gene was 0%. 
5.9 Detection of IMP Gene  
The IMP gene of 447 bp was amplified in all collected isolates by multiplex PCR as described 
above. Positive and negative controls were used. The band was detected for the gene and for 




Figure 19: IMP (447 bp) gene electrophoresis: *(+): positive control, (-): negative control, L: 
Ladder 
 
Results showed that all 50 study isolates were IMP gene negative; no bands appeared in the 
gel electrophoresis. As a result, the prevalence of the IMP gene was 0%. 
5.10 Detection of VIM and OXA-48 Genes by PCR 
The VIM gene of 390 bp and the OXA-48 gene of 438 bp were amplified in all collected 




Figure 20: VIM (390 bp) and OXA-48 (438 bp) genes electrophoresis: *(+): positive control, 
(-): negative control, L: Ladder 
 
The two genes were run at the same gel electrophoresis. Positive and negative controls were 
used. The band was detected for the gene and for the positive controls while none in the 
negative PCR blank (Fig: 20). Results showed that there was only one band appeared on the 
gel and it was the same size as the VIM positive control. As a result, isolate number one was 
VIM gene positive. It was collected from a blood culture specimen and it was also positive for 
aac-6'-ib gene but was KPC negative and it showed different patterns on PFGE. The 
prevalence of VIM gene was 2%. On the other hand, no bands appeared on the gel for OXA-
48 gene. The prevalence of this gene was 0%. 
5.11  Detection of NDM-1 Gene by PCR 
The NDM-1 gene of 621 bp was amplified in all collected isolates by multiplex PCR as 
described above. Positive and negative controls were used. The band was detected for the 




Figure 21: NDM-1 (621 bp) and OXA-48 (438 bp) genes electrophoresis: *(+): positive 
control, (-): negative control, L: Ladder 
 
Results showed that all 50 study isolates were NDM-1 gene negative; no bands appeared in 
the gel electrophoresis. As a result, the prevalence of the NDM-1 gene was 0%. 
5.12  Detection of aac-6-Ib Gene by PCR 
The aac-6-Ib gene of 482 bp was amplified in all collected isolates by multiplex PCR as 
described above. Positive and negative controls were used. The band was detected for the 
gene and for the positive control while none in the negative PCR blank (Fig: 22). 
 
 
Figure 22: AAC-6´-Ib (482 bp) and OXA-48 (438 bp) genes electrophoresis: *(+): positive 
control, (-): negative control, L: Ladder 
 
Results showed that 48 from 50 isolates were aac-6-Ib gene positive. Only two isolates were 
aac-6-Ib negative, isolate number 20 and 25. Isolate number 20 (urine specimen) was KPC, 
qnrA, qnrB, qnrS, IMP, VIM, NDM-1, OXA-48, and aac-6-Ib genes negative; this suggested 
that it has other multiresistance genes other than the study genes. Isolate number 21 (Swab 
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specimen) was negative for all the study genes except it showed a KPC positive gene. As a 
result, the prevalence of aac-6-Ib gene was the highest and recorded 96%. 
 
5.13  Comparison the Prevalence of the Study Genes in the Different 
Isolate Sources 
The KPC gene was detected in 82% of the isolates, while 8% were non KPC-producing 
organisms. Comparing the presence of KPC gene in the different isolate sources, swabs 
isolates were 89.0% KPC positive, followed by urine which was 87.5% of the isolates positive 
for KPC gene, then wounds isolates 76% and finally blood isolates 60% (Fig: 23). 
 
 
Figure 23: The KPC positive isolates in the different speciemens sources 
 
The qnrA, qnrS, IMP, OXA-48, and NDM-1 genes were not found in any of the research 
isolates. Urine, blood, wounds, swabs, and the other research isolates were all negative for 
these genes. 
The qnrB gene was detected in 2% of the isolates, while 98% were negative for this gene. 
Only one qnrB positive isolate was detected and was found in urine 6.25%. As for qnrB gene, 
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the prevalence for VIM gene was 2% of the isolates. The only positive VIM isolate was found 
in blood 20%. 
The aac-6-Ib gene was detected in 96% of the isolates, while only 4% were negative for this 
gene. Comparing the presence of aac-6-Ib gene in the different isolate sources, blood, 
wounds, sputum, tracheal secretions, biopsies, and anal smears were 100% aac-6-Ib gene 
positive, followed by urine 94% and then swabs 89%. 
In general, urine was found to have KPC, qnrB, and aac-6-Ib genes among its isolates, while 
blood was found to have KPC, VIM, and aac-6-Ib genes among its isolates. Wound, swabs, 
sputum, tracheal secretions, biopsies, and anal smears isolates were found to have only KPC 
and aac-6-Ib genes. 
5.14 Relation between Patients Age and Carbapenemase / QRDR-
Producing Organism’s Infections 
Results showed that the median age of the carbapenemases and/or QRDR genes producing 
organisms infected patients, was 53 years. Only one case was a child who was born in 2010. 
Results in this outbreak suggested that the old aged patients were more likely to have the 
infection. 
5.15 Relation between Patients Gender and Carbapenemase / QRDR-
Producing Organism’s Infections 
Male to female ratio was found to be 2,3:1. In KPC positive isolates the ratio was 3,1:1, while 
in aac-6´-Ib was 2,2:1. That means, in this outbreak male were more likely to have the 
infection than females (Fig: 24). 
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Figure 24: The infected male and female ratio 
5.16 Relation between Weather Temperature and KPC / aac-6´-Ib 
Genes Positive Isolates 
Results showed that isolates (KPC and aac-6’-Ib genes positive) in this outbreak were mainly 
collected in winter time (low tempareture). Most of them were from September to March. 
That means, In Summer time (April to August) there were few cases of patients infected by 
KPC and aac-6’-Ib producing organisms (table 2). 
 
Correlations 





aac-6'-ib Positive  
Leipzig Average 
Temperature  





Sig. (2-tailed)  .005 .001 
N 10 10 10 





Sig. (2-tailed) .005  .000 
N 10 10 10 







Sig. (2-tailed) .001 .000  
N 10 10 10 
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Correlations 





aac-6'-ib Positive  
Leipzig Average 
Temperature  





Sig. (2-tailed)  .005 .001 
N 10 10 10 





Sig. (2-tailed) .005  .000 
N 10 10 10 







Sig. (2-tailed) .001 .000  
N 10 10 10 
**. Correlation is significant at the 0.005 level (2-tailed).   
 
Table 2: Correlations for weather and infection relation 
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6 Discussion 
Beta-lactamases are emerging worldwide as acquired resistance in Gram-negative bacteria 
such as in the Enterobacteriaceae (Bush, 2001). The Enterobacteriaceae multidrug resistance 
problem is obviously increasing and causing limited treatment options. The morbidity, 
mortality, and the associated economic burden are very likely to increase dramatically due to 
theses organisms during the next decade (De Kracker et al., 2011). 
6.1 The Study Isolates 
In this study, we were looking for the presence of carbapenemase and QRDR genes (KPC, 
qnrA, qnrB, qnrS, IMP, VIM, NDM-1, OXA-48, and aac-6´-Ib) in clinical isolates collected 
during an outbreak in the University Hospital of Leipzig during the period from January 2011 
to October 2011. Out of the 50 isolates, results showed that the main carbapenemase and 
QRDR-producing organisms (44 isolate) were Klebsiella pneumoniae (88%), followed by two 
E. coli isolates (4%), two Enterobacter cloacae (4%), one Proteus mirabilis (2%), and one 
Acinetobacter baumanii (2%). 
Studies such as in Korea between 2004 and 2006, the qnrB gene was found mainly in 
Citrobacter freundii (67.9%) and Klebsiella pneumoniae (62.5%) followed by Enterobacter 
cloacae (15.8%) and E .coli (9.4%) (Tamang et al., 2008). 
In Korea, another study between 2005-2006 detected the aac-6´-Ib gene mainly in E .coli 
(53.8%) followed by Klebsiella pneumoniae (19%) and then Enterobacter spp (12.9%) (Kim 
et al., 2009). Another study in Nigeria showed that the highest prevalence of carbapenemase 
was found in Pseudomonas aeruginosa (38.55%) followed by E. coli (34.8%), Proteus 












E. coli   83 29 34.9 
P. aeruginosa  52 20 38.5 
K. pneumoniae  28 7 25.0 
P. mirabilis 37 11 29.7 
Total 200 67 33.5 
Table 3: Occurrence of Carbapenemase among the Clinical bacterial Isolates (Yusuf I et al., 
2012). 
 
6.2 The Source of the Study Clinical Isolates 
In this study, the major source of the collected clinical isolates (50 isolates) was from urine 
(16), followed by swabs (9), wound (7), and then Blood (5). 13 isolates were collected from 
other sources.such as sputum (3), tracheal secretions (5), anal smears (3), and biopsies (2). 
Multiple studies agreed with this result. In a study carried out by Manageiro et al. in 2012 to 
identify the resistance mechanisms of Enterobacteriaceae isolates, the majority of isolates 
were collected from the urine (57.4%) (Manageiro et al., 2012). Another study in Greece 
during a period of 3-years from January 2009 to December 2011, 73 carbapenemase-
producing Klebsiella pneumoniae isolates were collected. The most common type of sample 
from which these pathogens were isolated was urine (50%), followed by bronchial secretions 
(17.8%), blood samples (14.3%), pus (13.1%), and intravenous catheters (4.8%) (Poulou et 
al., 2012). 
On the other hand, a study carried out by Papaioannou et al. to determine the mechanisms of 
carbapenem resistance among multi-drug resistant Klebsiella pneumoniae (n=521) in a 
tertiary hospital, the study isolates were mainly collected from blood (119), followed by urine 
(97), then pus, catheters, and finally bronchial secreations (Papaioannou et al., 2013). Another 
study in South Africa carried out by Ehlers et al., the origins of the Acinetobacter baumannii 
isolates were 58% from sputum specimens, followed by 7% from urine specimens, 11% from 
blood cultures and 24% from diverse specimens (Ehlers et al., 2012). 
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In a study carried out in New York City, 19 isolates of Klebsiella spp producing carbapenem-
hydrolyzing beta lactamase were recovered from November 1997 to July 2002 from 7 
different hospitals. Eighteen were identified as K. pneumonia, and the remaining one was K. 
oxytoca. This study suggested the first cases of Klebsiella pneumoniae producing KPC to be 
detected in the United States (Bradford et al., 2004). 
Another study at the same period time also in New York City was carried out during the 
period of April 2000 to April 2001. Twenty-four patients in intensive care units at Tisch 
Hospital were colonized by carbapenem-resistant K. pneumonia. Fourteen of the 24 patients 
were infected. Out of the fourteen infected patients, eight patients died. This Klebsiella 
infection was considered the cause of.death. Furthermore, this study is considered the first 
cases of Klebsiella with this phenotype in the hospital (Woodford et al., 2004). 
6.3 The KPC Gene 
The KPC producers are found nowadays worldwide and considered endemic in several 
countries in Asia, South America, the Middle East, and Europe (Bush and Fisher, 2011, 
Nordmann et al., 2009). 
In our study results concerning KPC gene showed that out of 50 samples, 41 isolate were 
positive for the KPC genes while 9 isolates were negative and showed different patterns on 
pulsed field gel electrophoresis. The prevalence of the KPC gene was 82%. 
In China a surveillance study of carbapenem-resistant Enterobacteriaceae isolates was carried 
out in order to investigate the frequency and prevalence of KPC-type genes in Huashan 
Hospital. From January 2005 to March 2010, 109 nonduplicate Klebsiella pneumoniae 
isolates with resistance to ertapenem were collected. The presence of genes encoding β-
lactamases, including KPC-type and OXA-type carbapenemases were screened using PCR 
method and all amplified products were then subjected to direct nucleotide sequencing. 
Results of this study reported for the first time the frequency of KPC-2-type carbapenemases 
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among carbapenem-resistant K. Pneumoniae isolates in China. Furthermore, results showed a 
significant increase in the incidence of carbapenem-resistant K. pneumoniae isolates from 
0.9% in 2005 to 12.9% in 2009 which suggested being due to the failure to control the spread 
of these strains (Chen et al., 2011). 
In a prospective study carried out in the period from August 2006 to November 2006, a total 
of 108 Klebsiella pneumoniae isolates were collected from a hospital in the United States in 
order to determine the prevalence and genetic relatedness of KPC positive strains. Results 
showed that the prevalence of KPC-possessing Klebsiella pneumoniae in this institution has 
risen to 9.2% in four months (Tibbetts and Dunne, 2007). 
On the other hand, several outbreaks and sporadic cases of KPC-producing K. pneumoniae 
were reported in many places such as a study in Italy in 2009, Two cases isolates of 
carbapenem-resistant K. pneumonia obtained from patients at an Italian teaching hospital 
were collected. The first strain was obtained from a central venous device in a Crohn’s disease 
patient. The second was isolated from a urine sample from a urinary catheter in an ICU 
patient with a haematoma. As a result, KPC-2 was identified.In addition, it was found that it 
was the second documented appearance of a class A carbapenemase-producing isolate of K. 
pneumonia in Italy and was not associated with travel abroad (Fontana et al., 2010). 
Further  cases were found in Greece in the period from February 2008 until December  2008. 
Twenty one hospitals provided a total of 225 K. pneumonia isolates which were identified as 
possible KPC-producing isolates. As a result, 77% isolates from 18 hospitals were found to 
harbour the KPC-2 gene.The remaining 52 isolates were found to harbour the VIM gene 
(Giakoupi et al., 2009). 
6.4 The qnrA and qnrS Genes 
Results of our study showed that all the study isolates were negative for the qnrA, qnrS, IMP, 
OXA-48, and NDM-1 genes. On the other hand, the qnr genes were detected worldwide, i.e. 
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in Korea (Tamang et al., 2008), Iran (Saboohi et al., 2012), Hungary (Szabo et al., 2008), and 
in many different places around the world. 
A 368 clinical isolates were collected during 2004 to 2006 at Kyungpook National University 
Hospital in Korea. As a result, 141 (38.3%) isolates were qnr positive. The qnrA, qnrB, and 
qnrS genes were detected in 1.0%, 36,7%, and 0.5% of the isolates, respectively. These results 
agreed with our results in qnrB high percentage while qnrA and qnrS are very close to our 
results which showed 0% of these genes (Tamang et al., 2008). 
In Hungary 2002 until 2006, clinical isolates of 70 E. coli, 101 K. pneumonia, 5 Citrobacter 
freundii and 61 Enterobacter spp isolates were collected from two laboratories in Budapest to 
study the prevalence of qnrA, qnrB, qnrS and aac(6’)-Ib-cr genes. As a result, the prevalence 
was low: around 3% for qnrA, 0.8% for qnrB, 0.4% for qnrS and 8% for aac(6’)-Ib-cr genes 
(Szabo et al., 2008). 
In a study in Germany carried out during the period of 2000 to 2003 in Enterobacter spp and 
Citrobacter freundii isolates the qnrA gene was detected but the prevalence was stell low; 
among 703 clinical Enterobacteriaceae isolates from 34 German ICUs which showed 
resistance to cephalosporin or fluoroquinolone, four patients were qnrA gene positive (Jonas 
et al., 2005). 
Another research in the United Kingdom in Liverpool studied the prevalence of qnrA gene in 
47 blood culture isolates of Enterobacteriaceae. These strains were resistant to ciprofloxacin 
and cefotaxime. Results showed that the prevalence of the qnrA gene among these isolates 
were 32% and they included isolates of E. coli, Citrobacter freundii, Klebsiella pneumoniae 
and Enterobacter cloacae. This report was the first to address the qnrA gene identification in 
the United Kingdom and the prevalence was considered to be high (Corkill et al., 2005). 
In a study carried out by Saboohi and his colleagues, a total of 85 of isolates of Salmonella 
spp. were collected from different provinces of Iran during the years 2008 to 2010. Results 
showed the presence of qnrA, qnrB, and qnrS genes among the isolates. 22 of 85 (25.8%) 
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carried the qnrA gene, 1 (1.17%) qnrB and 1 (1.17%) qnrS gene and 1 isolate carried all the 
three genes. Furthermore, the resistance to quinolones and fluoroquinolones by these genes 
has been confirmed (Saboohi et al., 2012). 
In August 2012, a study described the prevalence of qnr determinants (qnrA, qnrB, and qnrS) 
in 19 fluoroquinolone-resistant Escherichia coli isolates from chicken litter. Results suggested 
the presence of qnrS and qnrA genes in these fluoroquinolone-resistant isolates. It has been 
suggested that the emergence and dissemination of fluoroquinolone resistant strains can be 
from the contaminated poultry by-products and be acquired by human beings via the food 
supply (Ponce-Rivas et al., 2012). 
In a collection of Enterobacterial isolates collected from the Biceˆtre hospital In France, a 
study was carried out to evaluate the prevalence of qnrA and qnrS genes. In this study the 
prevalence of the qnrA determinant was low (Poirel (B) et al., 2006). 
6.5 The NDM-1 Gene 
Compairing our results that showed no NDM-1 gene and low prevalence of VIM gene, a 
study was carried out in the period between April 2009 and February 2011 in Mubarak Al 
Kabeer Hospital in Kuwait disagreed with our results. This study aimed to identify the 
mechanisms of carbapenem resistance among fourteen clinical isolates. Eleven out of fourteen 
isolates produced VIM-4 in Klebsiella pneumoniae, E .coli, Enterobacter cloacae, and 
Klebsiella oxytoca while three isolates were NDM-1 positive in Klebsiella pneumoniae (Jamal 
et al., 2013). 
Multiple reports showed infected cases with NDM-1 positive organisms from patients who 
were in Indian subcontinent before, such as in the United Kingdom (Muir and Weinbren, 
2010). Enterobacteriacea isolates were studied from south India, north India, and from the 
UK's national reference laboratory. 44 isolates with NDM-1 were identified in south India 
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(Chennai), 26 in north India (Haryana), 37 in the UK, and 73 in other sites in India and 
Pakistan (Kumarasamy et al., 2010). 
In Australia, a multidrug-resistant E. coli isolate was recovered from a urine sample of a 67-
year-old man who had been hospitalized at St. George Hospital in Sydney. This patient was 
previously hospitalized in Bangladish and then transferred to Australia. Molecular 
investigations revealed the first identification of the NDM-1 gene in Australia (Poirel (B) et 
al., 2010). 
In India 2010, three carbapenem resistant Acinetobacter baumannii were isolated from 
patients in the ICU in a hospital in Chennai (Karthikeyan et al., 2010). As stated in this study, 
it the first report of the existence of NDM-1 gene in clinical isolates of Acinetobacter 
baumannii in India. Further reports were from the United States (Centers for Disease Control 
and Prevention, 2010). 
Investigations revealed that the NDM-1 gene was found in numerous clinical isolates from 
both nosocomial- and community-acquired Klebsiella pneumoniae and E. coli infections that 
were obtained from a wide geographic area of India subcontinent (Kumarasamy et al., 2010). 
Agreeing with our results in the absence of NDM-1 gene, a study used the PCR method to 
investigate the presence of the NDM-1 gene in a 210 clinical isoltes in tertiary hospitals in 
Samsun, Turkey. The isolates included different organisms such as Acinetobacter baumannii, 
Pseudomonas aeruginosa, Pseudomonas putida, Enterobacter cloacae, Enterobacter 
aerogenes, Klebsiella pneumoniae, Providencia rettgeri, E. coli, and Citrobacter freundii. As 
a result, the NDM-1 gene was not detected in any of the clinical isolates. This study together 
with other studies indicated the uncommon presence of the NDM-1 gene in Turkey (Yanik et 
al., 2013). 
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6.6 The OXA-48 Gene 
Our study showed no OXA-48 gene among the study isolates. On the other hand, Reports 
showed that OXA-48 producing organisms were detected such as in Tunisia (Ktari et al., 
2011), France (Cuzon et al., 2011), Morocco (Benouda et al., 2010), and Senegal (Moquet et 
al., 2011). 
In Tunisia between the period of October 2009 until March 2010, 153 clinical isolates were 
recovered from Sfax University Hospital. These isolates showed reduced susceptibility to 
extended-spectrum cephalosporins and/or imipenem. Results showed 21 isolates from 153 
(13.7%) were harbouring the OXA-48 gene (Ktari et al., 2011). 
In France from April 2010 to June 2010, 260 patients hospitalized in the ICU and the internal 
medicine unit at the hospital of Villeneuve-Saint-Georges were screened. Seven patients were 
infected by multidrug-resistant K. pneumonia isolates and hatboured the OXA-48 gene and 3 
were only colonized. Researcher of this study suggested a nosocomial transmission since in 
April 2010 only three patients were detected to be infected with a multidrug-resistnt K. 
pneumonia. The remaining cases were in contact with these cases and the infection was 
transmitted (Cuzon et al., 2011). 
The first detection of the OXA-48 gene in Enterobacteriaceae in Morocco was reported in a 
study carried out in 2010, where one patient was infected with carbapenem-resistant K. 
pneumonia. From this patient, two isolates were recovered and screened. Results showed that 
one of the isolates carried the OXA-48 gene while the other harboured another gene that was 
the OXA-1 gene (Benouda et al., 2010). 
Outbreaks of OXA-48-producing K. pneumoniae and other enterobacterial isolates have been 
also described. In the United Kingdom between January 2008 and April 2010, 20 K. 
pneumonia carbapenem resistant isolates were collected from 13 patients. The prevalence rate 
was found to reach 0.17%. The researcher reported this as an early and prolonged outbreak in 
the UK of K. pneumonia producing OXA-48 gene (Thomas et al., 2013). 
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In a single case study in Lebanon 2008, a 7-year-old female child complained from a 
prolongened urinary tract infection. K. pneumonia isolate showed multidrug resistance. PCR 
results were negative for TEM, SHV, CTX-M, GES, KPC, IMP, VIM, IMI, SPM, GIM, and 
SIM genes. The OXA-48 gene was the only positive gene that was found in this isolate. 
Researcher of this study considered this study as the first evidence of beta lactamase mediated 
carbapenem resistance in Enterobacteriaceae in Lebanon (Matar et al., 2008). The OXA-48 
gene was also detected in India in a study was described in a conference 2010 (Bell et al., 
2010). 
The OXA-48 producing organism was first identified in Klebsiella pneumonia clinical isolate 
in Turkey in 2004. The K. pneumonia was isolated in September 2001 at the Istanbul Faculty 
Hospital from a 54-year-old man with urinary tract infection and skin burns. This isolate was 
found to be resistant to all beta lactams, including carbapenems (Poirel et al., 2004). 
Also in Istanbul, Turkey 38 isolates were collected at the University Hospital of Istanbul in 
the period from May 2006 to February 2007. Results showed that all isolates were posistive 
for the OXA-48 gene. This study indicated the first large outbreak of OXA-48 positive 
carbapenem-resistant Klebsiella pneumoniae isolates (Carrer et al., 2008). 
Another study was carried in Germany in 2012 for nine carbapenem resistanct isolates 
collected from patients in five German hospitals. Results showed that six isolates were 
positive for the OXA-48 gene. Using the PFGE technique, a clonal transmission of an OXA-
48 producing Klebsiella pneumoniae strain was indicated in two hospitals. Considering the 
high frequency of population exchanges between Germany and Turkey, in addition to the fact 
that Turkey represents a main reservoir for the OXA-48 carbapenemase, this study speculated 
that at least some of the isolates emerging in Germany could be originated from Turkey 
(Pfeifer et al., 2012). 
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6.7 The IMP Gene 
Our study showed no occurance of IMP gene among the isolates. A study carried out in 2000 
by Takahashi A et al. at Gunma University Hospital disagreed with this result. Nine isolates 
from different inpatients were examined for the IMP gene by PCR method. All nine isolates 
were positive for this gene (Takahashi et al., 2000). 
Another study tested a total of 58 clinical isolates for the presence of KPC, GES, IMP, VIM, 
OXA-48 and NDM-1 genes. Thirty were detected to be positive for these genes by PCR 
method. These positive strains included 21 Enterobacteriaceae, 1 Acinetobacter baumannii 
and 8 Pseudomonas aeruginosa isolates (Monteiro et al., 2012). 
On the other hand, Moquet O et al., 2011 had the same result as in our study. November 2008 
to October 2009, eleven Enterobacteriaceae isolates were collected at the Institut Pasteur in 
Senegal for the presence of VIM, IMP, KPC, OXA-48 genes as well as CTX-M, OXA-1, and 
TEM beta lactamase genes, the aac(6´)-Ib aminoglycoside resistance gene and the quinolone 
resistance genes qnrA, qnrB, qnrS. These isolates included 8 Klebsiella pneumoniae, 1 E. coli, 
1 Enterobacter cloacae, and 1 Enterobacter sakazakii. The OXA-48 was detected in all 11 
isolates. The qnr and aac(6´)-Ib genes were detected in 7 isolates, while VIM, IMP and KPC 
genes were not detected (Moquet et al., 2011). 
6.8 The qnrB Gene 
The qnrB gene in our isolates was found in one isolate out of fifty collected. So the 
prevalence of this gene was 2% and is concedered low compairing to other studies. This 
isolate was found to carry in addition to the qnrB gene, the KPC gene as well as the aac-6´-Ib 
gene. 
In a study carried out in 2009 in Peru and Bolivia, a relatively high prevalence of qnrB (54%) 
and low qnrS (14%) was detected in commensal Enterobacteria from 310 healthy children. As 
they mentioned in this study, it was the first study on the prevalence of qnr genes in human 
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commensal bacteria and suggested that these bacteria could be an important reservoir of 
similar genes (Pallecchi et al., 2009). 
In another study carried out in Argentina in June 2013, the prevalence of plasmid mediated 
quinolone resistance (PMQR) genes such as qnrA, qnrB, qnrS, aac-6´-Ib-cr and other genes 
was investigated among 55 oxyiminocephalosporin-resistant enterobacteria collected in a 
previous survey. The main PMQR determinants were aac-6´-Ib-cr and qnrB in prevalence 
rates of 42.4% and 33.3% respectively (Cruz et al., 2013). 
On the other hand, qnrB gene was detected in a low prevalence in a study carried out between 
2005 and 2006. A total of 179 Gram negative bacterial strains collected in China were 
screened for qnrA, qnrB, and qnrS genes by using the PCR method. The qnrB gene was 
detected in 6.2% of E. coli and 7.69% of E. cloacae (Cai et al., 2011). 
Another study was carried out in Budapest, Hungary, to determine the prevalence of qnrA, 
qnrB, qnrS and aac-6´-IB-cr genes in ESBL-producing isolates. A total of 70 isolates were E. 
coli, 101 were Klebsiella pneumoniae, 5 were Citrobacter freundii and 61 were Enterobacter 
spp. These isolates were collected from seven different hospitals and clinics between the 
period from 2002 to 2006. As a result, the qnrB gene was detected only in two isolates: one 
Klebsiella pneumoniae and one Citrobacter freundii (Szabo et al., 2008). 
6.9 The VIM gene 
As a result of our study there was only one isolate which carried the VIM gene. This isolate 
was collected from a blood culture specimen and it was also positive for aac-6'-ib gene but 
was negative for the KPC gene. By doing the PFGE, it showed different patterns than the 
KPC positive isolates. The prevalence of VIM gene was found to be 2%. 
In 1999, VIM-1 as a new type of acquired metallo beta-lactamase was reported to have been 
found in an isolate of P. aeruginosa in Italy (Lauretti et al., 1999). VIM-2 isolates were 
detected in France in 1996 (Poirel et al., 2000; Poirel et al., 2001). 
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In October 2003, the first isolation of aVIM-2 from a Pseudomonas aeruginosa isolate in 
Germany was in a study carried out in Berlin from a blood culture of a 70-year-old male 
cancer patient during an episode of febrile neutropenia that followed a course of anticancer 
therapy. Posiitve result was identified for the presence of VIM gene. As the study researchers 
mentioned, this was the first isolateion of the VIM gene in Germany (Henrichfreise et al., 
2005). 
The VIM gene was also detected in Greece in a study between 1996 and 1998. A total of 
1,276 clinical isolates of P. aeruginosa were collected from 973 patients at a greek university 
hospital. Among those, 2111isolates were resistant to imipenem and meropenem. In sex 
isolates the resistance was associated with the production of VIM-1 gene (Tsakris et al., 
2000). 
An outbreak was also reported in Greece, at the University Hospital of Thessaly, between the 
period of 2001 to 2002 involving 47 VIM-producing Pseudomonas aeruginosa isolates 
showed that the VIM-4 gene had been identified (Pournaras et al., 2002; Pournaras et al., 
2003). While VIM-3 was reported in Taiwan in 10 clinical pseudomonas spp isolates out of 
209 collected isolates (Yan et al., 2001). The VIM-4 was detected in the United States as 
Tolman and his collegues (Tolman et al., 2002). The VIM-11 was detected in a study in 
Argentina November 2002. The study isolate was obtained from the catheter of a 7-month-old 
patient at the Hospital de Niños (Pasteran et al., 2005). 
In a study in 2008, the prevalence of ESBL and MBL antibiotic resistance genes in Klebsiella 
pneumoniae isolates were investigated in isolates collected from Pretoria Academic Hospital 
in South Africa. A PCR assay was used for the detection of four genes which include CTX-M, 
SHV, TEM and VIM genes in 97 Klebsiella pneumoniae isolates. Results showed that the 
VIM gene was not detected in any of the isolates analysed in this study (Maningi et al., 2008). 
On the other hand, a study was carried out in the largest teaching hospital (Mubarak Al 
Kabeer hospital) in Kuwait for fourteen carbapenem-resistant Enterobacteriaceae isolates 
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between April 2009 and February 2011. Results showed high VIM gene prevalence; Eleven 
out of fourteen produced the VIM-4 gene. It was found that six were in Klebsiella 
pneumoniae, three in E. coli, One in Enterobacter cloacae and one in Klebsiella oxytoca. 
Furthermore, the prevalence of NDM-1 gene was found to be low. Only three Klebsiella 
pneumoniae isolates produced the NDM-1 gene (Jamal et al., 2013).  
Another study was carried out in Saudi Arabia for a total of 350 clinical isolates of P. 
aeruginosa to determine the production of metallo beta-lactamase (MBLs) using PCR and 
DNA sequencing assays. As a result, all the study isolates harbour the VIM-2 gene that 
suggested the VIM gene as the dominant MBL gene in MBL-producing isolates in Saudi 
Arabia (Al-Agamy et al., 2011). 
Shehabi and his collegues in 2011 isolated strains from effluent water were highly polluted 
with VIM producing E. coli and P. aeruginosa similar to those observed frequently in clinical 
bacterial isolates. They suggested that his might contribute to increase accumulation of 
antimicrobial resistance in the natural environment (Shehabi et al., 2011). 
6.10 The aac-6-Ib Gene 
Our study results showed that 48 from 50 isolates were aac-6-Ib gene positive. Two isolates 
only were aac-6-Ib negative; one was isolated from urine and was negative for all study 
genes. The other one was isolates from a swab speciemen and was positive only for the KPC 
gene. As a result, the prevalence of aac-6-Ib gene was the highest and recorded 96%. 
In a study carried out in Korea by Kim YT and his collegues, reported the first published 
investigation in Korea of strains that included both aac(6')-Ib and aac(6')-Ib-cr variant. 85 
strains of suspected aac(6')-Ib positive isolates were collected. Among them, 38 strains were 
harbouring the aac(6')-Ib; the remaining 47 strains were harbouring the aac(6')-Ib-cr variant. 
Of these 47 strains, 19 harboured aac(6')-Ib and aac(6')-Ib- cr simultaneously (Kim et al., 
2011). 
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The aac(6′)-Ib gene was found to be detected worldwide, as discussed below, such as in the 
United States (Park et al., 2006), Italy (Frasson et al., 2011), Israel (Chmelnitsky et al., 2009), 
Brazil (Paiva et al., 2012) and many other places. 
In a study in the United States during the period from January 2005 to December 2006, 555 
Enterobacteriaceae isolates were examined for harbouring the aac(6′)-Ib gene. A total of 86 
isolates carried the aac(6′)-Ib gene, while 19 were positive for the aac(6′)-Ib-cr gene. Further 
investigation showed that one aac(6′)-Ib positive K. pneumonia isolate carried both aac(6′)-Ib-
cr and qnrS genes (Park et al., 2006). 
Frasson and his collegues studied a total of 197 enterobacterial isolates between the period of 
March 2008 untill May 2008 for the presence of the aac(6′)-Ib-cr gene recovered in an Italian 
teaching hospital of Padua, Italy. Twenty five isolates (13%) were found to harbour the 
aac(6′)-Ib gene and of these 16 (8%) harboured the aac(6′)-Ib-cr gene variant. It was found 
that the aac(6′)-Ib-cr gene was exclusively found in E. coli strains, while aac(6′)-Ib gene was 
found mainly in K. pneumonia in 8 isolates and E. coli in 1 isolate (Frasson et al., 2011). 
In Israel between 2004 and 2006, 47 KPC-producing K. pneumonia isolates were collected in 
Tel Aviv Medical Center. PCR experiment detected the aac(6′)-Ib-cr gene variant in six of the 
isolates which contributed 12.8% (Chmelnitsky et al., 2009). 
Another study was in Brasil between May 2009 to November 2009. 101 ciprofloxacin-
resistant E. coli isolates were collected in Belo Horizonte, Brazil. As a result, eight isolates 
harboured the qnr and the aac(6′)-Ib-cr genes. The study researchers reported these results as 
the first qnrB19, qnrS1 and aac(6′)-Ib-cr carrying E. coli isolates in Brazil (Paiva et al., 2012). 
In a study carried out in Bulgaria in a period between 2000 and 2005 to investigate the 
prevalence of aac-6´-Ib-cr gene among a total of 163 ESBL-producing enterobacteria. Of 
these, 52 isolates (52.5%) were aac-6´-Ib-cr positive and it was considered the first report of 
qnrB and aac-6´-Ib-cr in clinical Enterobacteriaceae isolates from a Bulgarian hospital 
(Sabtcheva et al., 2009). 
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Another study was carried out in China to investigate the prevalence of qnr and aac-6´-Ib-cr 
genes. A total of 265 clinical isolates were screened at nine teaching hospitals in China. These 
isolates include E. coli, Klebsiella pneumoniae, Citrobacter freundii, and Enterobacter 
cloacae. The qnrA, qnrB, qnrS, and aac-6´-Ib genes were detected by PCR assay. Results 
indicated the high prevalence of qnr and aac-6´-Ib-cr genes among the Enterobacteriaceae 
(Yang et al., 2008). 
On the other hand, among 555 nonduplicate enterbacterial blood culture isolates collected at 
Asan Medical Center in Korea, the aac-6´-Ib was detected in 15.5% Enterobacteriaceae 
isolates. This is considered low prevalence compairing to our results for the same gene (Kim 
et al., 2009). 
6.11 The Median Age 
This research studied the median age of the carbapenemases and/or QRDR genes producing 
organisms infected patients. Results showed that the median age was 53 years (born in 1958). 
Only one case was for a child who was born in 2010. Figure 25 showed the percentages of 
isolates that is related to a patient age. According to these results we suggested that the old 
aged patients were more likely to have the infection. 
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Figure 25: The percentages of isolates related to a patient’s age 
 
In a study included six out of seven patients with bloodstream infections caused by KPC-
producing Klebsiella pneumoniae was carried out during the period from January to April 
2005 in the ICU of a hospital in Manhattan. The patient´s median age was found to be 68 
years (Nadkami et al., 2009). 
In Chikago, swab samples from 33 patients were cultured for the detection of KPC gene. 
Results showed that the mean age of the patients infected with KPC-producing organisms was 
66 years (Thurlow et al., 2013). 
Another study carried out in New York City, nineteen isolates of KPC-producing Klebsiella 
spp were recovered from 7 hospitals. The median age of the 17 patients whom possessed KPC 
gene was 73 years (Bradford et al., 2004). 
Very close to our result, a study carried out in Brazil for a 43 isolates of carbapenem 
resistance Klebsiella pneumoniae- producing organisms, the median age of the patients who 
presented with KPC infection was 54.5 years (range, 37–74 years) (Bergamasco et al.,2011). 
As a conclusion in most studies, infections with carbapenemases as well as QRDR producing 
organisms were rare in children and adults and were most communly found in aged patients as 
they considered having lower immunity. Figure 26 summerizes the common patient ages who 




Figure 26: The median age for patients infected with Multidrug resistant organisms in 
some countries world wide. (i) Nadkami et al., 2009, (ii) Thurlow et al., 2013, (iii) 
Bradford et al., 2004, (iv) Bergamasco et al.,2011, (v) Pournaras et al., 2009. 
6.12 Male to Female Ratio 
Further results in our study indicated male to female ratio to be 2.3:1. In KPC positive isolates 
the ratio was 3.1:1, while in aac-6´-Ib was 2.2:1. That means, in this outbreak male were more 
likely to have the infection than females. 
In Greece, a study carried out in the period from October 2007 to September 2008 for 47 
patients showed that patients had a male to female ratio of 1.5 and a mean age of 59.5 years 
(Pournaras et al., 2009). 
On the other hand, 77 cases reported in questionnaires in Europe, 51 were originated from the 
UK. The male to female ratio was 0.62 and the patients’ age ranged from 2 to 87 years 
(Struelens et al., 2010). 
In Northeast India a study indicated that out of a 219 isolates, 19 were detected to produce 
carbapenemase. The male to female ration was found to be 1.37:1 and the patients’ age ranged 
from 5 days to 75 years (Bora and Ahmed, 2012). 
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6.13 The Study of Seasonal Variation  
In our study, results showed that isolates in this outbreak were mainly found in winter season 
(from September to March). While in summer season (April to August) there were only few 
cases (Fig 27). Infections caused by carbapenemases and QRDR-producing organisms were 
detected in winter time in some studies and in summer time in other studies. 
 
 
Figure 27: The relationship between Weather Temperature and KPC and aac-6’-IB positive 
genes 
A study was carried out from blood stream infections caused by KPC-producing Klebsiella 
pneumoniae in ICU in Manhattan. These isolates were collected during the winter time from 
January 2005 to April 2005 (Nadkami et al., 2009). Another study was carried out in the USA 
at the end of summer and the beginning of winter time, from August 2006 to November 2006 
(Tibbetts and Dunne, 2007). 
On the other hand, studies isolates were collected in summer or relatively high temperature 
time. Kim SY and his collegues detected the aac-6´-Ib gene in isolates collected in a period 
between March to July 2005 (Kimm et al., 2010). 
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Scientists from The Oregon State University, the University of Maryland School of Medicine, 
and researchers from the University of Florida and the Research Institute of the Hospital for 
Sick Children in Toronto found that bacterial infections increase during the summer time. 
They suggested but not proved that these findings were due to many resons; for example P. 
aeruginosa infections could be linked to more people swimming in lakes or pools during the 
summer. Furthermore, Cattle have higher bacterial shedding rates in the summer, and the peak 
of E. coli infections could be connected to higher consumption of ground beef or other factors 
during the "outdoor grill" season (Oregon State University, 2008). 
6.14 Additional Study Isolates Relationships  
 
Further statistical analyses were used to show the number of isolates which (table 4): 
1. carried the KPC gene and were negative for the aac-6'-ib gene. 
2. carried the aac-6'-ib gene and were negative for the KPC gene. 
3. Carried both the KPC and aac-6'-ib genes simultaneously. 
 
KPC gene * aac-6'-ib Crosstabulation 
   aac-6'-ib 
Total    0 1 
KPC gene 0 Count 1 8 9 
Expected Count .4 8.6 9.0 
1 Count 1 40 41 
Expected Count 1.6 39.4 41.0 
Total Count 2 48 50 
Expected Count 2.0 48.0 50.0 
Table 4: The KPC and aac-6'-ib genes Crosstabulation 
6.15 Prevalence of Carbapenemases and QRDR Genes 
Data from reported to the CDC from 2007 indicated that 8% of all Klebsiella isolates were 
carbapenem-resistant K. pneumoniae (CRKP), in comparison with <1% in 2000 (Srinivasan 
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and Patel, 2008). Since 2008, four different bacterial strains (3 Enterobacter cloacae and 1 
Klebsiella pneumoniae) were isolated from the rectal swabs of 2 patients admitted to the 
Caritas Baby Hospital (CBH) in Bethlehem, Palestine. These isolates were resistant to at least 
one of the carbapenems (ertapenem, imipenem, and meropenem). All isolates were KPC-2 
positive and showed the presence of different combination of plasmid encoded beta-lactamase 
genes such as TEM, SHV, OXA-1, MIR-1, GES-23, and KPC-2 in these isolates. These 
isolates were resistant to all beta-lactam antibiotics, co-trimoxazole, and gentamycin (Kattan 
et al., 2012). 
During the period of 1995-2002, isolates were collected at the tertiary-care hospital in Korea 
to investigate the phenotypic and genetic properties of metallo beta-lactamase producing 
Pseudomonas isolates. The prevalence of imipenem resistance (IMP) among Pseudomonas 
aeruginosa isolates reached 16% in 1997, when 9% of the resistant organisms were found to 
produce VIM-2 β-lactamase (Lee et al., 2002). 
A multicenter study in Greece reported that 62.1% of imipenem-resistance P. aeruginosa 
strains were VIM-2-producers and were detected in nine of the 15 hospitals examined in 2001 
(Giakkoupi (B) et al., 2003). 
In a study carried out In Iran in 2013, 100 P. aeruginosa isolates were included in this study. 
83 isolate (83%) were resistant to imipenem. Among these resistant isolates 48 (57.9%) were 
metallo beta-lactamase producers. Using PCR 6 isolates were positive for IMP gene type 
IMP-1, while no VIM gene was detected (Fallah et al., 2013). 
In 2012, a study was carried out in Northeast India for 219 K. pneumoniae isolates showed 
that a total of 19 isolates were screened for carbapenemase production. . All the screening 
positive isolates (n =19) were found to be positive for the plasmid mediated blaNDM-1 gene 
by PCR. Out of these 19 isolates 57.89% were from urine, 15.79% were from sputum, 10.53% 
were from blood and 15.79% were from pus. The screening positive isolates were also found 
to be positive for the modified Hodge test. The age of the patients with the NDM-1 positive 
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isolates ranged from 5 days to 75 years and the male to female ratio was 1.37:1 (Bora and 
Ahmed, 2012). Due to lack of epidemiological data within India, the exact prevalence of 
NDM-1 enzyme is not known. 
From October 2009 to March 2010, 153clinical isolates of K. pneumoniae with reduced 
susceptibility to extended-spectrum cephalosporins and/or imipenem werer collected from 
Sfax University Hospital, Tunisia. Among these isolates, 21 (13.7%) was found to be 
blaOXA-48 gene producers. In 20 OXA-48-producing isolates, the blaOXA-48 gene was 
observed to be transferable to Escherichia coli strain. The only one remaining OXA-48 
positive isolate was suggested to be chromosomally located (Ktari et al., 2011). 
In a study carried out at Kyungpook National University Hospital in the Republic of Korea, 
368 non duplicate clinical isolates of Enterobacteriaceae were collected during the period of 
2004 to 2006 which were resistant to nalidixic acid and at least to one of the extended-
spectrum-beta-lactams (cefoxitin, cefotaxime, cefepime, aztreonam, or ceftazidime). Results 
showed that a total of 141 (38.3%) isolates were qnr positive. The qnrA (1.0%), qnrB 
(36.7%), and qnrS (0.5%) were detected but none of the isolates had two or more types of 
these genes simultaneously. Furthermore, results detected the qnrB mostly in Citrobacter 
freundii isolates (67.9%), followed by K. pneumoniae (62.5%), Enterobacter cloacae 
(15.8%), and Escherichia coli (9.4%) isolates. While qnrA was detected only in E. cloacae 
isolates and qnrS was detected in one K. pneumoniae and one E. coli isolate (Tamang et al., 
2008). 
Another study for identification of Qnr genes to detect qnrA, qnrB, and qnrS genes was 
carried out in a Taiwanese university hospital in 2004. 526 nonreplicate clinical isolates of 
Enterobacter cloacae were collected. Results showed that eighty-six (16.3%) of all isolates 
were qnr positive; qnrA1 (0.6%), qnrB1 (10.1%), and qnrS1 (6.5%) (Wu et al., 2007). 
During the period from January 2005 to December 2006, a study was carried out at Asan 
Medical Center in Korea to detect the presence of aac-6-Ib gene among 555 nonduplicate 
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enterobacterial isolates collected from blood cultures. The aac-6′-Ib gene was detected in 
15.5% Enterobacteriaceae isolates. Among these aac-6′-Ib-positive isolates, 12.9% were 
Enterobacter spp., 53.8% Escherichia coli isolates, 19.0% Klebsiella pneumoniae isolates. 
They suggested that there was a strong association between aac-6′-Ib-cr and OXA-1 and 
CTX-M-1 group β-lactamase genes. Furthermore, they investigated that one aac-6′-Ib-positive 
K. pneumoniae isolate carried both aac-6′-Ib-cr and qnrS (Kim et al., 2009). 
6.16 Epidemiology of Carbapenemases and QRDR Genes 
6.16.1  Europe 
In 2005, the first report of a clinical isolate producing a KPC outside of the USA occurred in 
France from a patient who had been hospitalized in New York City (Naas et al., 2005). 
KPC-producing isolates have been reported from several European countries including, 
Poland. A single case study was reported on a 56-year-old patient with no travel history who 
was admitted to a cardiology ward in a Warsaw hospital. PCR and sequencing identified the 
presence of KPC-2 gene (Baraniak et al., 2009). In the UK, 2 isolates were studied. The first 
K. pneumoniae was isolated in 2007 from an elderly male in a Scottish hospital. The second 
isolate was from London in 2008 from an elderly female who was admitted into a hospital in 
Israel. The KPC gene was detected by PCR in both isolates (Woodford et al., 2008). 
In areas such as Greece where KPCs are now considered endemic, many outbreaks have 
occurred (Nordmann et al., 2009). Epidemic situations of KPC-2 have also been reported in 
Greece in a 12-month period study. Between the period of October 2007 to September 2008, 
47 clinical isolates were obtained from Hippokration University Hospital for a K. pneumoniae 
strains that showed reduced susceptibility to carbapenems and were positive for 
carbapenemase production. PCR results showed that all isolates carried the KPC-2 gene 
(Pournaras et al., 2009). 
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Another study in Greece was a single case study in 2007 for a 22 year-old woman who was 
hospitalized in the ICU of the hospital of Heraklion for severe cranial trauma with coma. PCR 
and sequencing identified beta lactamase genes coded for KPC-2 and TEM-1 (Cuzon et al., 
2008). 
The Enterobacteriaceae-producing KPCs have also been recently reported in Italy and 
Finland in a research that studied two cases. The first case was a patient transferred from 
Greece to Finland in June 2009. This isolate was a K. pneumoniae  strain. PCR and 
sequencing confirmed harbouring of the KPC-2 gene. Case two was for a patient who was 
transferred from north-western Italy to Finland in August 2009. By PCR and sequencing, the 
isolate was found to harbour the KPC-2 gene (Osterblad et al., 2009). 
In Germany in the period from July 2010 to January 2011, an outbreak of KPC-2 and VIM-1 
was reported in the ICU department of the University Hospital Essen. Carbapenem-resistant 
K. pneumoniae strains were isolated from seven patients (5 men and 2 women). The patients 
age ranged from 22 to 72 years. Three of four patients were died from these strains. As the 
study researchers mentioned, this report was the first of the detection of a carbapenem-
resistant Enterobacteriaceae producing KPC-2 and VIM-1 outside of Greece (Steinmann et 
al., 2011). 
The VIM was first isolated in Verona, Italy, in 1997. The study was a single case study for a 
clinical isolate from an Italian inpatient at the Verona University Hospital. This isolate was a 
carbapenem-resistant P. aeruginosa. Sequencing of the gene showed that it harboured a new 
class B beta lactamase that was then named VIM-1 (Lauretti et al., 1999). 
The fluoroquinolone resistance was reported in many studies; in Barcelona, Spain during the 
period from 1992 to 1997, a study carried out on the evolution of quinolone resistance 
revealed that the prevalence of fluoroquinolone resistance in the feces of healthy people was 
high, 24% in adults and 16% in children (Garau et al., 1999; Oteo et al., 2005). 
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The aac(6′)-Ib gene was found to be detected worldwide such as in Italy in a study discussed 
previously (Frasson et al., 2011). 
6.16.2 The Americas 
To date, KPC-producing bacteria have been isolated in at least 33 states (Kitchel et al., 2009). 
The first KPC isolates Klebsiella pneumoniae was found in the United States in North 
Carolina in 2001 and then spread in New York (Yigit et al., 2001; Patel et al, 2009; Kitchel et 
al., 2009). 
KPCs and its derivatives were also considered endemic according to many outbreaks in many 
areas in USA such as the north-eastern USA (Nordmann et al., 2009). A citywide surveillance 
study was carried out in Brooklyn. A total of 602 isolates were collected from an outbreak in 
2 hospitals. Of 602 isolates of K. pneumoniae collected, 45% had ESBLs. Of the ESBL 
producing isolates, 3.3%  harboured the KPC-2 gene (Bratu (B) et al., 2005). 
In New York, 3 patients cases were studied: the first patient was a 44-year-old man 
recovering from a kidney transplantation in January 2003. PCR confirmed that this isolate 
harboured the KPC-2, TEM-1, and SHV-12 genes. The second patient was a 39-year-old man 
who experienced multiple trauma in April 2005. PCR showed that this isolate carried the 
KPC-2 gene. Finally, the third patient was a 41-year-old woman who was at the end-stage of 
renal disease. After her hospital admission, K. pneumoniae was identified. PCR analysis 
confirmed that this isolate harboured the KPC-2 gene (Lomaestro et al., 2006). 
In the ICUs of a hospital in Manhattan, seven patients with bloodstream infections caused by 
K. pneumonia isolates were identified between January 2005 and April 2005. PCR confirmed 
that all isolates harboured the KPc gene and sequencing identified the KPC-2 gene. Further 
results showed that the median age was 68 years (Nadkarni et al., 2009). 
In a study carried out by Park and his colleagues, the aac(6′)-Ib gene was found in 50.5% of 
isolates, and of these, 28% carried the cr variant (Park et al., 2006). 
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6.16.3 Africa and Middle East 
The NDM-1 (New Delhi metallo-beta-lactamase) gene containing organisms have emerged 
and are now spreading in all continents. The first reported case of the NDM-1 (name New 
Delhi) was in the Indian origin of which was in 2009 in a Swedish patient who travelled to 
New Delhi and acquired a UTI caused by carbapenem resistant Klebsiella pneumoniae and E. 
coli strains (Yong et al., 2009). 
In a study carried out by El-Herte and his colleagues, three patients from Iraq whom 
carbapenemase-producing E. coli or K. pneumonia were recovered, were admitted to the 
American University of Beirut Medical Center in July 2010. The first two patients had 
leukemia diagnosed upon arrival. The third patient had a complicated transurethral resection 
of the prostate. PCR results showed that the first isolate harboured the OXA-48 gene, the 
second produced both OXA-48 and NDM-1 genes, while the third isolate carried only the 
NDM-1 gene. They reported the first Iraqi patients referred to Lebanon from whom 
carbapenem resistant Enterobacteriaceae were recovered (El-Herte et al., 2012). 
Between the years 2009 to 2011, 28 carbapenem resistant Enterobacteriaceae isolates were 
collected in the United Arab Emirates. Among these isolates 3 Klebsiella pneumoniae, 2 
Escherichia coli, 1 Enterobacter cloacae and 1 Citrobacter freundi were identified to produce 
NDM-1 carbapenemase. These findings strongly support the assumptions that, beyond the 
Indian subcontinent, the Middle East is an important reservoir of NDM producing organisms 
(Sonnevend et al., 2013). 
The first KPC outbreak outside the USA was in Israel. During 2004 and 2005, six patients 
were infected with carbapenem-resistant K. pneumoniae and admitted to the Tel Aviv Medical 
Center. During 2006, this number increased to reach 45 patients. Using PCR, the KPC gene 
was not found in any carbapenem-resistant K. pneumoniae strains in 2004. On the other hand, 
93% (43 of 46) of the isolates collected from 2005 to 2006 carried the KPC gene. After 
sequencing, 60% of the KPC isolates identified as KPC-3 producer and the remaining were 
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KPC-2 genes. This research noticed a sharp increase in carbapenem-resistant K. pneumoniae 
strains harbouring KPC gene in Tel Aviv Medical Center from 2004 to 2006 (Leavitt et al., 
2007). 
KPCs in Israel considered endemic and epidemic, and many outbreaks have been reported 
(Nordmann et al., 2009; Leavitt et al., 2007;). In February 2005, an imipenem-resistant E .coli 
strain was isolated from a 75-year-old woman hospitalized at Tel Aviv Medical Center. 
During September and October 2005, three additional carbapenem-resistant E. coli isolates 
were detected. PCR confirmed the presence of the KPC-2 gene in the four isolates (Navon-
Venezia et al., 2006). 
Quinolone resistance is worldwide distributed. In the period from March 2003 to July 2007, a 
total of 141 E. cloacae islates were collected from the microbiology laboratories of eight 
different hospitals in Algeria: five located in the centre of Algiers, two located in the east of 
Algiers, and the last located in the west. As a result, the qnr genes were detected only in five 
quinolone-resistant ESBl-producing isolates; four had the qnrS1, and one had the qnrB1. This 
report considered the first report for the QnrS1, QnrB1 and QnrB4 in areas such as Algeria 
(Iabadene et al., 2008). 
6.16.4 Asia 
The first identified acquired metallo beta-lactamases was IMP-1, it was detected in a clinical 
isolate of S. marcescens from Japan in 1994 (Osano et al., 1994). A study in Japan from April 
to May 1993, 105 strains of metallo beta lactamase producing Serratia marcescens were 
isolated from seven hospitals located in Aichi Prefecture. The results confirmed that 4 of 105 
strains of S. marcescens tested have the IMP gene. The study researchers considered theses 
findings suggested a local prevalence of imipenem-resistant S. marcescens strains that carry 
the IMP gene (Ito et al., 1995). 
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In addition to the KPC producing isolates in USA, they have been reported from several 
countries outside the USA including China (Wei et al., 2007). A study carried out by Wet ZQ 
and his collegues in 2004, a carbapenem-resistant K. pneumoniae strain was isolated from the 
sputum of a 75-year-old patient hospitalized in the ICU on November 2004. As a result, a 
carbapenem-resistant isolate of K. pneumoniae harbouring KPC-2 was detected in Zhejiang, 
China. 
Another study in Singapore 2011, indicate the presence of community acquired KPC 
producing Enterobacteria (Venkatachalam et al., 2012). 
A study carried out in China from pediatric patients characterized by a high prevalence of 
plasmid-mediated quinolones resistance; they found that 4.1% were positive for qnr and 8.2% 
for aac(6′)-Ib-cr genes. They have known to confer low-level fluoroquinolone resistance or to 
inactivate ciprofloxacin, but not moxifloxacin (Han et al., 2010). 
In Vitnam during September 2011, samples from seepage water were collected. The NDM-1 
was detected in 3 Klebsiella pneumoniae isolates (Isozumi et al., 2012). 
6.16.5 Latin America and Scandinavian Countries 
KPC-producing isolates have now been reported from several Scandinavian countries such as 
a study carried out in Sweden and Norway in 2009. All the study isolates expressed a 
multidrug-resistant phenotype. PCR results indicated that the isolates collected from Norwey 
harboured the KPC-2 gene while the isolates collected from Sweden harboured the KPC-3 
gene. The study researchers reported this study as the first KPc-producing K. pneumoniae 
isolates in Norway and the second isolate from Sweden (Samuelsen et al., 2009). 
KPC-producing isolates have now been reported from several countries in Latin America such 
as Colombia, Brazil, Trinidad and Tobago (Monteiro et al., 2009; Akpaka et al., 2009; 
Villegas et al., 2007). In Brazil between September 2006 and November 2006, four 
carbapenem-resistant K. pneumoniae strains were isolated from patients hospitalized in an 
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ICU of a hospital located in Recife city. These isolates were obtained from blood (2 isolates) 
and urine (2 isolates). PCR indicated that all the study isolates harboured the KPC gene. This 
study considered the first detection of KPC-2 producing K. pneumoniae strains in Brazil 
(Monteiro et al., 2009). 
In Trinidad and Tobago 2006, a 63-yar-old male patient was admitted to a hospital in Mount 
Hope. As a result, the isolate was positive for the presence of carbapenemase. PCR analysis 
indicated the KPC gene and sequencing was performed and confirmed the KPC-2 gene 
(Akpaka et al., 2009). 
Another study carried out in Colombia in January 2006, four isolates were collected from a 
tertiary care center in Medellin. Three isolates were Pseudomonas aeruginosa and one isolate 
was a Citrobacter freundii. As a result, the isolates carried the KPC-2 gene. It was the first 
report of a KPC-type beta lactamase identified not in an Enterobacteriaceae family (Villegas 
et al., 2007). 
In Peru and Bolivia, a study suggested a remarkable prevalence of qnrB (54%) and, at a lower 
level, of qnrS (14%) in pools of commensal enterobacteria from 310 healthy children 
(Pallecchi L et al., 2009). In 2010, VIM-1 producing Klebsiella pneumonia isolate was 
detected in Denmark (Hasman et al., 2010). 
Nordmann and his collegues summerized the world wide distribution of K. Pneumoniae 
carbapenemase (KPC) as well as the geographic distribution of VIM and IMP genes in figures 




Figure 28: A) Worldwide geographic distribution of K. Pneumoniae carbapenemase (KPC) 
producers. Gray shading indicates regions shown separately: B) distribution in the United 




Figure 29: Worldwide (A) and European (B) geographic distribution of Verona integron–
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Beta lactam resistance producing isolates of Enterobacteriacea and non-Enterobacteriacea 
have emerged since more than seventy years ago (Abraham and Chain, 1940). They are 
known to cause both community and hospital-acquired infections. Resistance against 
carbapenem is primarily mediated by the production of enzymes that destroy the beta lactam 
antimicrobials, which are produced by these isolates involving the expression of serine and 
metalobetalactamase genes KPC, IMP, VIM, NDM-1 and OXA-48. Quinolone resistance is 
predominanty mediated by mutations in the qnrA, qnrB, qnrS, and aac-6-Ib genes. 
Carbapenemase-producing organisms especially Klebsiella pneumoniae carbapenemases 
(KPCs) emerged as important pathogens especially among critically ill patients causing 
significant morbidity and mortality. This study aims to determine the prevalence and types of 
quinolone resistance and carbapenemases genes among different isolates from patients 
admitted to the University Hospital of Leipzig over a period of ten months. 
During the period from January 2011 through October 2011, a total of 50 carbapenemases 
isolates were recovered from patients of the University Hospital of Leipzig/ Germany. The 
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isolates were identified by biochemical tests and their susceptibility to antimicrobials was 
determined by the microbroth dilution method according to ISO standard. The KPC, IMP, 
VIM, OXA-48, NDM-1, and aac-6-Ib genes as well as qnrA, qnrB, and qnrS genes were 
detected by multiplex PCR, respectively. 
Results showed that KPC gene was detected in 82% of the isolates while 8% were KPC 
negative. The qnrA, qnrS, IMP, NDM-1, and OXA-48 genes were not detected in any of the 
isolates while qnrB and VIM genes were found in 2%. On the other hand, aac-6-Ib gene was 
the most prevalent gene among the study isolates and composed a percentage of 96%. Results 
also showed that KPC, and aac-6-Ib genes were detected in isolates collected from urine, 
blood, wounds, swabs, sputum, tracheal secretions, biopsies, and anal smears, while VIM 
gene was detected in one isolate collected from blood. The qnrB gene was found in one 
isolate collected from urine specimen. 
The wide spread of carbapenem and quinolone resistance-producing organisms is a critical 
problem that complicates the treatment of infections resulting from these organisms. 
Necessary measures must, therefore, be taken to limit their spread, which include appropriate 
antibiotic treatment, control of hospital infections, observe of personal hygiene, and the use of 
appropriate methods of sterilization and disinfection to prevent the dissemination of these 
organisms. 
Keywords: Resistance, carbapenemases, QRDR, multiplex PCR, antimicrobials 
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8 Conclusion 
Based on results of this study, Klebsiella pneumoniae carbapenemase gene and aac-6-Ib gene 
of Quinolone resistance determining region were the major genes found in strains of an 
outbreak at the University Hospital of Leipzig being responsible for a variety of serious 
infections. The main organisms that were found to be responsible for the infections were 
maily Klebsiella pneumoniae followed by E. coli and Enterobacter cloacae, then 
Acinetobacter baumanii and Proteus mirabilis. Sources from where the isolates were 
collected were urine, followed by blood, then swabs, and finally wounds. 
The KPC gene was mainly found in organisms collected from urine, followed by wounds, and 
finally blood. While qnrB, VIM genes were found in one isolate collected from urine and 
blood, respectively. The most prevalent quinolone resistance determining region gene was 
aac-6-Ib and it was found in 100% of the isolates collected from blood, wounds, sputum, 
tracheal secretions, biopsies, and anal smears, followed by urine 94% and then swabs 89%. 
On the otherhand, qnrA, qnrS, IMP, OXA-48, and NDM-1 genes were not found in any of the 
isolates. 
The median age of infection with carbapenemase /QRDR producing organisms was 53 years 
and males were more likely to be infected than females. Results showed a significant 
relationship between infections caused by carbapenemase and/or QRDR producing organisms 
and the weather time, infections increased mainly in winter time with lower tempareture and 
decreased in summer. 
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No. Sample Name 
Date 
of 







1 BK751 Alona 1960 
Blood 
Culture 16.01.2011 N 
Different 
Pattern N N N N N N N P E. coli 
2 VA1160 Eva 1951 
Anal 
smear 17.01.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
3 VA1755 Roswitha 1940 
tracheal 
secretions 24.01.2011 P 
The 
Same 
Pattern N N N N N N N P P. mirabilis 
4 VA1619 Eva 1951 
bronchial 
secretions 21.01.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
5 UR927 Christine 1951 
Midstream 
urine 21.01.2011 N 
Different 
Pattern N N N N N N N P K. Pneumoniae 
6 VA1796 Daniel 1989 
throat 
swab 24.01.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
7 VA2835 Nico 1991 
tracheal 
secretions 05.02.2011 N 
Different 
Pattern N N N N N N N P A. baumanii 
8 VA1785 Manfred 1944 
Swabs, 
perineum 24.01.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
9 VA1884 Daniel 1989 
Wound 
secretions 24.01.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
10 UR13282 Horst 1941 
Kath. 
Urine 22.10.2011 P 
The 




11 UR13327 Waltrand 1952 
Midstream 
urine 24.10.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
12 UR12331 Waltrand 1952 
Midstream 
urine 03.10.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
13 VA22374 Ralph 1963 
tracheal 
secretions 15.09.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
14 VA22695 Birgit 1948 
Swabs, 
perineum 19.09.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
15 VA22360 Ralph 1963 Swabs 15.09.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
16 VA25100 Udo 1957 
Wound 
secretions 18.10.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
17 UR11440 Jörg 1963 
Midstream 
urine 13.09.2011 N 
Different 
Pattern N N N N N N N N K. Pneumoniae 
18 UR12615 Waltrand 1952 
Midstream 
urine 10.10.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
19 VA24262 Waltrand 1952 
Wound 
secretions 08.10.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
20 UR2602 Olaf 1961 
Kath. 
Urine 27.02.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
21 UR2443 Willy 1935 
Midstream 
urine 23.02.2011 P 
The 
Same 
Pattern N P N N N N N P K. Pneumoniae 





23 VA3751 Willy 1935 Sputum 15.02.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
24 VA2969 Alexander 2010 tube tip 07.02.2011 N 
Different 
Pattern N N N N N N N P K. Pneumoniae 
25 UR2210 Jörg 1963 
Midstream 
urine 17.02.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
26 VA15976 Marion 1950 Bl 28.06.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
27 VA21335 Wolfgang 1955 Sputum 01.09.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
28 TP3823 Werner 1948 
chair 
(stuhl) 20.08.2011 N 
Different 
Pattern N N N N N N N P E. cloacae 
29 VA21856 Gerhard 1938 
tracheal 
secretions 08.09.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
30 VA13125 Fabian 1981 Swabs 27.05.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
31 UR3594 Erika 1941 
Midstream 
urine 20.03.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
32 VA8677 Peter 1955 Punctate 09.04.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
33 UR6147 Daniel 1989 
Kath. 
Urine 16.05.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 





35 UR7569 Peter 1958 
Midstream 
urine 16.06.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
36 UR3269 Pascal 1984 
Midstream 
urine 14.03.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
37 VA6259 Anja 1983 
Wound 
secretions 14.03.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
38 BU5595 Doris 1945 
Blood 
Culture 24.04.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
39 UR3062 Ralph 1940 
Midstream 
urine 08.03.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
40 UR2602 Olaf 1961 
Kath. 
Urine 
(Dark) 27.02.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
41 UR5786 Peter 1958 
Midstream 
urine 09.05.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
42 XX10454 Gerda 1929 
Swabs, 
Nasal 01.05.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
43 VA10454 Gerda 1929 
Swabs, 
Nasal 01.05.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
44 VA6262 Anja 1983 
Wound 
secretions 
abdomen 14.03.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
45 VA9481 Olaf 1961 
Anal 
smear 18.04.2011 P 
The 




46 BK526 Fritz 1953 
Blood 
Culture 10.01.2011 N 
Different 
Pattern N N N P N N N P E. cloacae 
47 SU241 Ralf 1940 Biopsie 28.01.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
48 VA2318 Peter 1960 
Wound 
secretions 
abdomen 31.01.2011 P 
The 
Same 
Pattern N N N N N N N P K. Pneumoniae 
49 VA2360 Alona 1960 
Wound 
secretions 
abdomen 31.01.2011 N 
Different 
Pattern N N N N N N N P E. coli 
50 VA3873 XXXX XXXX Swabs 16.02.2011 N 
Different 
Pattern N N N N N N N P K. Pneumoniae 
    SUM 
50 
Samples 41 P 
41 Same 
Pattern 0 1 0 1 0 0 0 48  
 
App. 1: The Study isolates summary table 
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